Friday, November 6, Background: Preclinical data indicate activity of mammalian target of rapamycin (mTOR) inhibitors, as well as synergistic activity together with radiotherapy in glioblastoma. The aim of this non-comparative randomized phase II trial (NCT01019434) was to assess the therapeutic activity of the mTOR inhibitor temsirolimus, in patients with newly diagnosed glioblastoma with unmethylated O6 methylguanine-DNAmethyltransferase (MGMT) promoter. These patients are in particular need for new treatment options as they derive little if any benefit from the currently standard temozolomide treatment.
Background: Wee1 is a protein kinase that plays a key role in regulating the G2 checkpoint and homologous recombination (HR) in response to DNA damage. Recent studies have demonstrated activity of the WEE1 inhibitor, AZD1775 (previously MK1775), in cancers with loss of the tumor suppressor TP53, including colon, pancreatic and breast. Hence, we hypothesize that WEE1 would be an ideal target for monotherapy in small cell lung cancer (SCLC), which is marked by ubiquitous loss of TP53. Moreover, because Wee1 inhibition induces a HR deficient state, dual targeting of Wee1 and PARP (another promising target previously identified in our group and in clinical trial testing) may induce synthetic lethality. In the present study we evaluate the efficacy of AZD1775 alone and with the PARP inhibitor, olaparib, in SCLC and investigate potential predictive biomarkers by proteomic profiling.
Experimental procedures: We evaluated the gene expression of WEE1 in SCLC tumor sample (n=23) compared to normal lung (n=42). We then treated with AZD1775 +/-olaparib SCLC cell lines (n=10). Drug sensitivity (IC50) was correlated with baseline expression level of 200 total or phosphorylated proteins measured by reverse phase protein array (RPPA) to identify potential predictive markers. SCLC cell lines with AZD1775 resistance (n=3) were treated with TP0903 (10, 20, 40, 80nM) in combination with AZD1775 (0.1nM to 1uM) to test the efficacy of AXL co targeting in augmenting WEE1 inhibitor response.
Results: SCLC tumors have a significantly higher gene expression level of WEE1 as compared to normal lung (p<0.07×10-6). Single-agent WEE1 or PARP inhibition decreased viability of SCLC cells in a dose-dependent manner with AZD1775 being more potent as a single agent treatment (IC50 <100nM in 70% SCLC cell lines) than olaparib (IC50 <1uM in 20% of SCLC cell lines) in a 6day assay. Combination of AZD1775 with olaparib revealed an additive effect in vitro in 90% of SCLC cell lines. Proteomic analysis revealed an association between WEE1 inhibitor resistance and higher levels of AXL and total S6K (p<0.05 for both). In contrast, WEE1 inhibitor sensitivity was associated with elevated basal expression of PDK1 (p<0.002), treatment of SCLC cells with the AXL inhibitor TP0903 (40nM) re-sensitized cells to AZD1775 (IC50 <10nM) in a 6day assay.
Conclusion and significance: The therapeutic options for patients with SCLC are limited and survival is poor. The WEE1 inhibitors are currently in clinical trials for SCLC. However, as with any targeted therapy, primary and secondary drug resistance is an important barrier to clinical benefit which could potentially be addressed with therapeutic combinations. In this study we show the over expression of WEE1 in SCLC and its efficacy as a single agent and in combination with olaparib. Here we also show that the activity of the WEE1 inhibitors might be limited in cancer cells overexpressing of AXL and that AXL inhibition re-sensitized the cells to AZD1775. Our work supports further exploration of the combination of PARP and WEE1 in SCLC and also the possibility of AXL inhibition as a mechanism to overcome WEE1 inhibition resistance in SCLC.
Acknowledgement: This work was supported by Uniting Against Lung Cancer grant (LB).
Novel Assay Technology
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Profiling cell free DNA in breast cancer and non-small cell lung cancer using broad NGS assessment. Nadia Solovieff Introduction: Cell free DNA (cfDNA) has become a promising approach for non-invasive assessment of the tumor genome. Many cfDNA assays target hotspot alterations in a focused set of genes, but do not provide a broad characterization of the cancer. We have developed and optimized a large next generation sequencing (NGS) panel covering the coding regions of over 500 genes. Using this panel, we sequenced cell free DNA from plasma and matched tumor DNA in patients with early stage breast cancer, late stage breast cancer and late stage lung cancer.
Methods: Plasma was collected from patients with cancer using a double spin protocol and, when available, matched archival tumor tissue (representing different time interval with blood collection) was obtained. Next generation sequencing libraries were generated from cell free DNA isolated from 70 plasma samples and genomic DNA from 58 matched tumor samples. The NGS libraries were enriched for the gene panel of interest and were sequenced to a targeted depth of 1,000X for plasma and 300X for matched tumors. We optimized parameters of standard bioinformatics tools to robustly call low allelic fraction events, detecting single nucleotide variants down to 1%, as well as indels and copy number alterations.
Results: We identified 8 PIK3CA hotspot alterations in plasma from late stage breast and lung cancers, in addition to many alterations across driver genes such as AKT1, EGFR, IDH2, NRAS, PTEN and TP53. In plasma samples from patients with late stage breast cancer, we found 4 ESR1 mutations exclusive to the plasma samples, of which 3 are known resistance mutations to endocrine therapy. Copy number alterations in EGFR, CCND1 and KRAS were also identified in patient plasma. When comparing the number of alterations across tumor stages, we found that late stage breast (mean = 12.5 variants) and lung cancers (mean = 12.5 variants) had a larger number of alterations present in plasma than early stage breast cancers (mean = 4.5 variants). We compared somatic mutations calls in plasma and matched tumor samples and found a concordance of 53%-67% at the variant level across patients with late stage cancers (N=37 pairs). Higher variant level concordance was observed among plasma-tumor pairs collected less than a year apart (N=11 pairs; 76%-84%) versus more than 5 years apart (N=8 pairs; 41%-50%).
Late-Breaking Abstracts
Conclusion: We have developed and optimized a 500+ gene panel for direct sequencing of cfDNA, and we demonstrate that this broad assessment of circulating tumor DNA can be used for non-invasive characterization of the cancer genome landscape. The number of alterations identified in patient plasma is consistent with higher levels of ctDNA being present in late stage disease than in early stage disease. The time dependent degree of concordance between plasma and tumor collection suggests that cell free DNA assays may provide a more accurate characterization of the current tumor mutational landscape than an archival tumor sample. The identification of plasma specific ESR1 alterations highlights the importance of cfDNA in the context of identifying mechanisms of resistance, particularly for metastatic disease when tumor tissue collection may not be feasible. In addition, a broad NGS panel provides the opportunity to identify lesions unevaluated by targeted assays and to discover resistance mutations.
LB-A06
Analysis of gene expression and protein expression of the AXL receptor in clinical biospecimen. Kristina Bernoth, Florian T. Unger, Nicole Lange, Hartmut Juhl, Kerstin A. David. Indivumed GMBH, Hamburg, Germany.
Introduction: It has become obvious that targeted therapy of patients has to be monitored by taking and analyzing biopsies on a regular basis. Therefore, laboratory methods have to be optimized to be able to handle minute amounts of clinical biospecimen, e.g. biopsies. In this study we are presenting the development of a Simple Western Size assay and a quantitative Real-time PCR assay for the detection and analysis of AXL protein and gene expression in biopsies.
Background: Targeted therapy in personalized medicine is often affected by resistance mechanisms, such as activating mutations of signaling molecules and signaling pathway bypasses. AXL, a tyrosine kinase receptor, is expressed in a variety of cancers and has been revealed as the most highly expressed gene in preclinical models with acquired resistance, and second most common alteration in EGFR (epidermal growth factor receptor) inhibitor-resistant tumors, behind the T790M mutation. Up-regulation and/or activation of AXL are shown to be predictive for lack of response to ErbB family receptor-targeted inhibitors, e.g. to Her2-targeted agents.
Methods: Protein expression was examined by Simple Western Size technology and gene expression was analyzed using quantitative Real-time PCR. For assay development, high and low AXL expressing breast cancer cell lines were used to establish "fit for purpose" assays. Subsequently, Her2-positive and Her2-negative samples from breast cancer patients were analyzed by screening for AXL gene and protein expression. Furthermore, correlations of gene and protein expression were conducted.
Results: In this study, we developed and validated an assay for the detection of AXL protein expression using the Simple Western technology. This highly sensitive technology enables high-throughput screening of extremely small sample amounts such as biopsies or laser capture microdissected material. Our results showed a broad linear dynamic range of AXL protein in both, high and low AXL expressing cell lines as well as a high reproducibility between multiple runs. The protein loading range suitable to detect AXL within whole cell lysates showed detection levels of AXL protein down to 10 ng of total protein. AXL protein expression results were highly comparable to AXL gene expression results in analyzed breast cancer cell lines and breast cancer patient samples. This newly developed assay will allow us to analyze and quantify AXL protein expression profiles in breast cancer tissue and subsequently correlate them with e.g. Her-2 expression status.
Conclusion: The elucidation of networks and mechanisms underlying drug resistance will greatly improve the development of new compounds and promote personalized therapy. In order to gain scientific knowledge regarding gene and protein expression of resistance relevant marker, e.g. AXL, it is mandatory to establish assays that are very robust, sensitive and furthermore, if not most important, applicable to biospecimen being collected in the clinical setting.
LB-A07
Using impedance-based approaches for measuring cell-mediated cytotoxicity and antibody-dependent cell-mediated cytotoxicity (ADCC). Leyna Zhao, Yama Abassi. ACEA Biosciences, San Diego, CA.
The most common method for measuring cell mediated cytotoxicity is the release assay based on the loss of target cell membrane integrity. Within up to 4 hours following effector cell addition resulting in target cell lysis, either the radioactive release from target cells pre-labeled with Chromium-51 or Indium-111 is measured, or the release of naturally occurring substances, such as lactate dehydrogenase (LDH), into the culture medium is assayed. Release of these substances thus serves as an indirect measure of the extent of cell damage due to effector cell-mediated target cell lysis. Alternative endpoint methods also include flow cytometry, enzyme-linked immunosorbent assay-based granzyme measurement, and morphometric analyses by microscopy.
Here we describe an impedance-based real-time label-free method that can automated capture the kinetics of the cell mediated or antibody-dependent cell mediated cytolysis (ADCC) of the target cancer cells. To determine if cell-mediated cytotoxicity, and specifically ADCC, can be investigated using an impedancebased xCELLigence system, the response of tumor cells (as target cells) to natural killer (NK) cell activity (as effector cells), in the presence or absence of immunoglobulin G isotype-specific antibody, was measured. Importantly, it is shown that the addition of NK cells in suspension, over a monolayer of adherent tumor cells, does not produce impedance changes, because the NK cells do not come in contact with the electronic sensor. However, the secretion of perforins and granzymes by these non-adherent NK cells does activate caspases inducing tumor cell apoptosis. Dysfunctional and dying tumor cells detach from the sensor electrode, reducing the number of viable and adhering cells on the electrode surface.
Overall, our results show that the impedance-base technology is a label-free alternative to the traditional end-point assays. The automated readouts provide direct, sensitive and specific measurement of target cell changes both short-term (hrs) and long-term (days). It allows the easy quantification of the cell-mediated cytotoxicity and evaluation of the potencies for specific antibodies.
Other Topics
LB-A08
ALK and ROS-1 status: A retrospective analysis in solid tumors. Maria Silvia Cona, matteo Duca, Adele Testi, Sara Cresta, Katia Fiorella Dotti, Alice Indini, Diego Signorelli, Giuseppe Pelosi, Filippo Guglielmo de Braud, Silvia Damian. Istituto Nazionale Tumori . Milan, Milan, Italy.
Background: Tyrosine kinase receptors are important regulators of cellular signal transduction pathways that play a crucial role in development of cancer. Among them, Anaplastic Lymphoma Kinase (ALK) and CRos Oncogene-1 (ROS-1) are activated by rearrangement in several tumors. Tailored therapies have been developed according to the status of ALK and ROS-1, successfully used in NSCLC and potentially useful in other solid tumors harboring ALK and ROS-1 aberrations.
Material and methods: ALK and ROS-1 status was evaluated in 666 and 441 patients with solid tumors, respectively, since 2014 at the Pathology Department. ALK and ROS-1 rearrangement and gene copy number variation (CNV) were assayed by fluorescence in situ hybridization (FISH). Gene copy number gain was defined by 3 to 5 fusion signals on average in ≥10% of cells, with amplification being highlighted by the clusters or 10 to 15 fusion signals in 10% or more tumor cells.
Results: ALK status was assessed in 650/666 (97%) cases, while ROS-1 status was evaluable in 426/441 (96%). We identified 15/650 (2.3%) cases with ALK rearrangment, including 13 lung adenocarcinomas (4.1%), 1 colon cancer (0.5%) and 1 myoepithelioma (0.5%). CNV for ALK was documented in 53% lung adenocarcinoma, 50% pancreatic, 41% biliary and 37% colon carcinoma patients. We found 7/426 (1.6%) tumors with ROS-1 rearrangement, corresponding to 5 lung (2.7%) and 2 colon (1.3%) adenocarcinomas.
Late-Breaking Abstracts
CNV for ROS-1 was more frequent in melanoma (77%), neuroendocrine tumors (39%) and NSCLC (32%, 3/4 cases of ROS-1 amplification were squamous carcinoma). Eight out of the 22 rearranged cases (5 ALK and 3 ROS-1) were tested for both genes: these aberrations were mutually exclusive. Three out of 5 (60%) ALK rearranged tumors showed ROS-1 deletion. No ALK and ROS-1 alterations were documented in 30 pancreatic, 25 H&N, 22 biliary tract, 13 renal, and 13 breast carcinomas, as well as in 13 melanomas and 36 other solid tumors.
Conclusions: ALK and ROS-1 rearrangement was found in 4.1% and 2.7% of NSCLC, respectively, in keeping with literature data. In other solid tumors, the percentage of rearrangements is exceedingly low, but melanoma, neuroendocrine tumors, pancreatic and colon cancer may show significant CNV. We speculate that such aberrations of ALK and ROS-1 could act as potential therapy targets, but additional investigation by immunohistochemistry and next generation sequencing is clinically warranted. Introduction: Plausibility of a causal role between vitamin D status and supplementation with cancer has been debated. Some epidemiologic studies of deficiency status, dietary vitamin D intake, and circulating 25-hydroxyvitamin D (25OHD) blood levels suggest a protective role, while other studies indicate no association.
Methods: We computed a vitamin D genetic risk score (VitD-GRS, range 0 to 10) based on unweighted allele count of five known genetic variants of vitamin D status to perform a Mendelian randomization analysis among 23,294 women of European ancestry in the US-based Women's Health Study. Participants were initially free of cancer (mean age 54.7 years) and prospectively followed for up to 20 years. We conducted age-adjusted Cox proportional hazards regression models to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for a 1-allele increase in VitD-GRS with total cancer (excluding non-melanoma skin cancer) incidence (3985 events) and mortality (770 events), as well as major site-specific cancers (breast, colorectal, and lung).
Results: Greater VitD-GRS was significantly associated with higher levels of circulating 25OHD in a subgroup of 1,782 cancer-free women with available genotyping and baseline 25OHD blood levels (mean 25OHD ranged from 52.1 to 71.5 nmol/L for 1 to 10 alleles, respectively; p for trend <0.0001). In Cox models, the VitD-GRS was not associated with total cancer incidence (3985 events, HR=1.01, CI=1.00 to 1.03, p=0.17) or cancer death (770 events, HR=1.00, CI=0.96 to 1.04, p=0.90). For specific cancer sites, the VitD-GRS was not associated with incident breast cancer (1560 events; HR=1.02, CI=0.99 to 1.05, p=0.21), colorectal cancer (330 events; HR=1.06, CI=1.00 to 1.13, p=0.066), or lung cancer (329 events; HR=1.00, CI=0.94 to 1.06, p=0.89).
Conclusions: In a long-term prospective study of women, we found no evidence that the potential inverse association between vitamin D and cancer incidence or mortality may be causal. The association of vitamin D with carcinogenesis may not depend on circulating vitamin D. Future studies should continue to evaluate potential explanatory pathways such as local and systemic immunity and circulating vitamin D.
Signal Transduction Modulators
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The carcinogenic role of CYP1B1 in cancer cells related to Wnt/β-catenin signaling and uPAR pathway. Yeo-Jung Kwon, Sangyun Shin, Dong-Jin Ye, Hyoung-Seok Baek, Young-Jin Chun. ChungAng University, Seoul, Korea.
Cytochrome P450 1B1 (CYP1B1) belongs to the CYP1 family and shares the feature as an enzyme for oxidative metabolisms. It has been reported that CYP1B1 expression is higher in the tumor tissues than the normal ones, especially in hormone-related cancers such as breast, ovarian, and prostate cancer cells. To explore the role of CYP1B1 on cancer cell proliferation, we studied the effects of CYP1B1 inhibition and activation in MCF-7 and MCF-10A cells. Here, we confirmed that expression of CYP1B1 affects the level of cell proliferation using CCK assay. To elucidate whether the cell proliferation induced by CYP1B1 is related to Wnt/β-catenin signaling, we examined the alteration of β-catenin and expression using western blot, RT-PCR, immunostaining, and qPCR followed by over-expression of CYP1B1 or treatment with DMBA (7,12-dimethylbenz[α] anthracene), a well-known CYP1B1 inducer and these studies also performed when CYP1B1 gene was knockdown or cells were treated with TMS (tetramethoxystilbene), a specific CYP1B1 inhibitor. These investigations all showed that CYP1B1 promotes β-catenin expression in mRNA and protein levels and induces β-catenin nuclear localization. To identify the effect of CYP1B1 on Wnt/β-catenin signaling further, the promoter activity of β-catenin/TCF/LEF or expression level of Wnt/β-catenin signaling target genes such as c-myc, cyclin D1 were examined and all factors also showed to be up-regulated by CYP1B1. To elucidate whether CYP1B1 induces cell metastasis, cell migration and invasion assay were conducted and it has been identified that CYP1B1 enhances cell motility by induction of mesenchymal-like cell morphological changes. Moreover, the uPAR-uPA pathway has been identified to be related to the CYP1B1-induced cell metastasis by detection of uPAR-uPA pathway factors using western blot and qPCR in MCF-7 and HeLa cells. Taken together, these data suggest that CYP1B1 promotes cell proliferation and metastasis via inducing Wnt/β-catenin signaling and uPAR pathway.
LB-A11
Expression of steroid sulfatase induces the integrin signaling pathway in HeLa cells. Dong-Jin Ye, Yeo-Jung Kwon, Sangyun Shin, Mihye Hong, Hyoungseok Baek, Seung-Ki Ahn, Dongwon Shin, Young-Jin Chun. Chung-Ang University, College of Pharmacy, Seoul, Korea.
Steroid sulfatase (STS) is responsible for the hydrolysis of aryl and alkyl steroid sulfates. STS has a pivotal role in regulating the level of estrogen and androgen responsible for growth of hormone-dependent tumors, such as breast or prostate cancer. However, the molecular function for tumor growth of STS is still not clear. To elucidate possible role of STS on cancer cell proliferation, we investigated whether STS is able to regulate integrin signaling pathway. In this study, we observed that overexpression of STS in HeLa cells induces the expression of integrin β1 and fibronectin, a ligand of integrin α5β1 at protein and mRNA levels. Dehydroepiandrosterone (DHEA), one of the main metabolite of STS, also induces mRNA and protein level of integrin β1 and fibronectin. We found that STS expression and DHEA enhance phosphorylation of focal adhesion kinase (FAK) at tyrosine 925 residue. Moreover, phosphorylation of ERK at threonine 202 and tyrosine 204 residues was also induced, indicating that STS may activate Ras/Raf/MEK signaling pathway. In conclusion, these results suggest that STS expression and DHEA may enhance Ras/Raf/MEK signaling through upregulation of integrin β1 and activation of FAK.
LB-A12
New target for cancer metabolism: Steroid sulfatase. Sangyun Shin, Yeo-Jung Kwon, Dong-Jin Ye, Hyoung-Seok Baek, Young-Jin Chun. Chung-Ang University, Seoul, Korea.
Steroid sulfatase (STS) expression has been considered to play a pivotal role in estrogen-dependent cancers. STS is known as a target enzyme for suppressing estrogen-mediated carcinogenesis. STS is able to convert estrogen sulfate to estrone form, like dehydroepiandrosterone sulfate (DHEA-S) to its' active form dehydroepiandrosterone (DHEA). Aerobic glycolysis is a hallmark of cancer metabolism. Lactic acid production was also increased by STS and DHEA.STS and its' major product DEHA reduced Oxygen consumption rate. STX064, a STS specific inhibitor inhibited DHEA formation and lactic acid production, recovered mitochondria resperation in HeLa cells. Hypoxia inducing factor 1 subunit HIF1α is recognized as an important regulator of aerobic glycolysis. To elucidate whether STS is able to regulate cancer metabolism, the effects on aerobic glycolysis were determined. STS overexpression significantly converted DHEA-S to DHEA. STS and the major product DHEA enhanced HIF1α protein, mRNA, promoter activity in HeLa cells. Glycolytic enzymes such as hexokinase 2 (HK-2) and glucose transporter (GLUT) were increased by STS overexpression and DHEA treatment in protein and mRNA levels. When cells were treated with HIF1α siRNA, all glycolytic enzymes induced by STS and DHEA were down-regulated. STS also regulated pyruvate kinase M (PKM)splicing. STS up-regulated PKM2 level and inhibited PKM1 level through transcription factor c-Myc. Phosphorylation of PKM2 was also induced by STS. In conclusion, STS and the major product DHEA may regulate aerobic glycolysis via HIF1α induction and c-Myc related PKM2 alternative splicing.
Target Identification and Validation

LB-A13
Cellular characterization of the selective inhibition of UBA5 by organometallic, adenosine-based inhibitors. Sara R. da Silva Cells that undergo higher protein turnover, such as pancreatic secretory cells and cancerous cells, have the propensity to undergo endoplasmic reticulum (ER) stress. If left uncorrected, ER stress can result in the initiation of apoptosis. To avoid these fates, cells have developed support systems to counteract the apoptotic effects of ER stress, such as conjugation of certain stress-associated proteins with the ubiquitinfold modifier 1 (UFM1) ubiquitin-like protein. Our research has recently focused on the discovery and in vitro validation of the first selective inhibitor of the UFM1 pathway, 5C-Z, which selectively targets the UFM1 E1 enzyme (UBA5) over other related enzymes and a panel of over 90 human kinases. This novel strategy of inhibiting UBA5 and subsequent UFMylation would make cancer cells that are highly dependent on this system more susceptible to pharmacological disturbances in ER homeostasis, which could lead to the use of milder drug dosing strategies. Our current efforts are focused on studying the effects of 5C-Z on intracellular signalling, the cellular distribution of proteins in the UFM1 pathway, and phenotypic changes within a lung cancer cell lung line (Sk-Luci6). Treatment of lung cancer cells that exhibit high levels of UBA5 protein expression results in decreased cell proliferation (EC50 = 216.9 μM, 95% C.I. = 211.5 -222.5 μM), yet does not induce cell death in other diseased (A549) or healthy (MRC9) lung cells (up to 200 μM). The decreased cellular proliferation upon 5C-Z treatment mirrors the effect of treatment with UBA5 siRNA. Using immunocytochemistry, it appears that treatment with 5C-Z also induces changes in both cellular morphology and the distribution of UBA5-like staining within the cell. Furthermore, there is an apparent decrease in UFM1-like co-localization with its E2 conjugating enzyme (UFC1) after prolonged incubation with 5C-Z, although further intracellular analysis is required to confirm this observation. Preliminary work also indicates that these cellular effects may also be selective against the UFM1 pathway compared to related ubiquitin-like labelling pathways. We are currently evaluating the effects of 5C-Z on ER stress signalling pathways connected to the UFM1 labelling system.
LB-A14
Targeting BAG3-dependent paracrine loop reduces growth and metastatic spreading of pancreatic adenocarcinoma. Incidence and death rate of Pancreatic Ductal Adenocarcinoma (PDAC) has increased in recent years, therefore the identification of novel targets for treatment is extremely important. Interactions between cancer and stromal cells are critically involved in tumor formation and development of metastasis. We have recently shown (manuscript in press) that PDAC cells secrete BAG3 that binds and activates macrophages trough a specific receptor (IFITM2), inducing their activation and the secretion of PDAC supporting factors.
Treatment with a murine monoclonal antibody (AC-2) targeting BAG3 reduced tumor growth and impaired metastasis formation in mouse models. Here we report further characterization of the in vivo activity of the antibody. Moreover, we have now successfully generated humanized variants of the AC-2 antibody and report the in vitro and in vivo activity of the humanized antibodies. Both appear to have the ability to inhibit macrophage activation in vitro and reduce tumor growth in PDAC models to an extent comparable to the murine parental antibody (AC-2).
In conclusion, we have identified a novel paracrine loop involved in PDAC growth and metastatic spreading and shown that its pharmacological blockage with an anti-BAG3 antibody has therapeutic potential for PDAC treatment.
Therapeutic Agents: Other
LB-A15
IACS-010759 is a novel inhibitor of oxidative phosphorylation that selectively targets AML cells by inducing a metabolic catastrophe. Jennifer R. Molina Acute myeloid leukemia (AML) is a highly aggressive disease with a high mortality rate that encompasses several genetically and clinically diverse hematological malignancies characterized by clonal expansion of transformed stem/progenitor cells with limited ability to differentiate into mature blood cells. Standard of care for AML has progressed minimally in the past 30 years for relapse/refractory AML, with survival rates of <12% for those aged >65 years. Therefore, novel, highly effective therapeutics are needed for this population. Targeting bioenergetic susceptibilities is an exciting area of oncology therapeutics that is potentially applicable in AML. Our group and others have shown that AML blasts depend significantly on mitochondrial oxidative phosphorylation to meet their energy and biomass production demands. Through an extensive medicinal chemistry campaign IACS-10759 was identified as a potent, selective inhibitor of complex I of the electron transport chain with excellent PK and a suitable overall profile. In AML cell lines and primary AML blasts treated ex vivo, we observe a robust decrease in proliferation and a concomitant increase in apoptosis with EC50 values of less than 10 nM. Response to IACS-10759 in AML cells was associated with induction of a metabolic catastrophe that negatively impacted the cells' ability to sustain energy homeostasis, amino acid biosynthesis, and nucleotide production. In a primary AML patient derived xenograft model from a patient who was refractory to standard of care and salvage therapies, 42 days of IACS-10759 (QDx5/week) treatment at 10 mg/kg extended the median survival by greater than 2-fold. Inhibition of OXPHOS by IACS-10759 was confirmed in AML cell lines and PDX models by a decrease in oxygen consumption and significant changes in gene and protein expression, non-essential amino acids and nucleotides. Due to the robust response in AML cell lines, primary AML samples ex vivo, and in vivo efficacy in primary AML PDX models, IACS-10759 has been advanced through IND enabling studies with first-inhuman studies targeted for the second quarter of 2016. Breast cancer is a major cause of cancer related death in United States women, and there is an urgent need for novel targeted therapies with low toxicity and increased efficacy. The TRAIL pathway has been of interest in the field of oncology, but resistance has been identified in cancer cell lines and primary tumors including those of the breast. Only a subset of triple negative breast cancers (TNBC) is sensitive to TRAIL, with other breast cancer molecular subtypes being resistant (Rahman et al., Breast Cancer Res. Treat., 2008) . Clinical translation of these findings has been limited, as TRAIL receptor agonistic antibodies have shown minimal effects.
We identified a small molecule inducer of the TRAIL pathway, ONC201/TIC10 (Allen et al., Sci. Trans. Med., 2013) that functions through dual inhibition of AKT/ERK, induction of the ATF4/CHOP pathway (Kline et al., Submitted, 2015) and cytotoxic effects dependent on TRAIL/DR5 upregulation. Recently, ONC201 completed its first-in-man phase 1 clinical trial in advanced solid tumors that defined its safety, pharmacokinetics and recommended phase II dose (Stein et al., Abstract C138, 2015 AACR-EORTC meeting).
The objective of this work was to investigate ONC201 efficacy in TNBC (TRAIL-sensitive) and non-TNBC (TRAIL-resistant) cells. Using cell viability assays, we demonstrate IC50 values for ONC201 in the low micromolar range for both TNBC (n=6) and non-TNBC cells (n=5). These doses are achievable based on human PK. The evaluated non-TNBC cell lines, including those with estrogen receptor positivity and HER2 amplifications, have been shown to be highly resistant to TRAIL therapy. Propidium iodide staining and analysis of SubG1 DNA content indicates that ONC201 induces apoptosis in both TNBC and non-TNBC cells. We also show that a single dose of ONC201 is well tolerated and efficacious in vivo against the MDA-MB-231 triple negative human breast cancer xenograft model. The effects of ONC201 on well-known mechanisms of TRAIL-resistance, such as increases in inhibitor of apoptosis (IAP) family proteins, were investigated to explain sensitivity of TRAIL-resistant breast cancer cells to ONC201. We observed that ONC201 mediates a decrease in expression of IAP family proteins XIAP, c-IAP1, and c-IAP2 across TNBC and non-TNBC cell lines. We have shown that XIAP levels correlate with sensitivity to ONC201-induced apoptosis (Kline et al., Submitted, 2015) . We also examined levels of death receptors DR4 and DR5 using flow cytometry, as a known mechanism of TRAIL resistance involves constitutive death receptor endocytosis from the cell surface (Zhang et al., Mol. Cancer Res., 2008) . Interestingly, increases in cell surface DR4 and DR5 levels are greater in TNBC cell lines when compared with non-TNBC cell lines.
Overall, our findings suggest that ONC201 exerts cytotoxic effects against a broad range of breast cancer cells, including TNBC and non-TNBC subtypes. These effects are observed regardless of the TRAIL sensitivity of the cells, and may be mediated through mechanisms involving downregulation of anti-apoptotic proteins and upregulation of cell surface death receptors. Our work will further understanding of these mechanisms and contribute to development of a preclinical rationale for the use of ONC201 as a treatment for breast cancers.
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Hospital volume determines mortality amongst neutropenic cancer patients within the United States. Yaacov Richard Lawrence, Damian Urban, Tal Sella, Jair Bar, Raanan Berger, Jeffrey Goldstein, Einat Shacham-Shmueli, Zvi Symon, Talia Golan. Sheba Medical Center, Ramat Gan, Israel.
Introduction: Hospital Volume is associated with improved outcomes in cancer surgery, and some aspects of cancer care. The influence of hospital volume on outcomes in neutropenic patients is unknown. Neutropenia secondary to bone-marrow suppression is a common, and dangerous complication of cancer treatment. Known factors associated with increased mortality include age, race and co-morbidities. We hypothesized that large-volume hospitals would have reduced mortality rates for neutropenic patients compared with small-volume institutions.
Methods: We utilized the NIS database of the Healthcare Cost and Utilization Project, focusing on the years [2000] [2001] [2002] [2003] [2004] [2005] [2006] . Only inpatient episodes with a diagnosis of both neutropenia and cancer were included in the study. Hospital volume was defined as the number of neutropenic cancer episodes listed for each institution per year. Mortality was defined as death during admission.
Results: 155,512 hospitalizations were included in the study, from 3049 different institutions. Median age was 60 years. The overall inpatient mortality was 7.1%. Mortality increased with patient age, for instance amongst those aged 30-39 years it was 4.3% compared to 10.7% for those aged 70-79 years. The average number of "neutropenic" inpatient episodes in each institution per year ranged from less than one to 225 (median 22.7). The population was split into four equal groups based upon hospital volume. Mortality was 8.5%, 7.7%, 7.0% and 5.2% for each group (from lowest to highest volume), likewise % discharged home was 77.3%, 82.4%, 85.2% and 90.1% (for both p<0.001). In a logistic regression model incorporating age, race and sex, 'hospital volume' remained statistically associated with reduced mortality (p<0.001).
Conclusion: Neutropenic patients hospitalized in large-volume institutions have a substantially lower mortality and a higher likelihood of returning home compared to those hospitalized at low-volume institutions. Our findings have implications for the setting in which phase I/II clinical trials of combination treatments with new biological agents and cytotoxic therapies be performed.
LB-A18
Combination therapy of carmustine and selenite targets AR full length and AR variants: New hope for patients with castration-resistant prostate cancer. Vijayalakshmi Thamilselvan, Mani Menon, Sivagnanam Thamilselvan. Vattikuti Urology Institute, Henry Ford Health System, Detroit, MI.
The major obstacle for successful treatment of advanced prostate cancer is the development of resistance to androgen ablation therapy leading to castration resistant prostate cancer (CRPC). Evidence strongly suggests that the androgen receptor (AR) and AR variants in CRPC build resistance to anti-cancer drugs, including next-generation therapies such as abiraterone and MDV3100 that target AR signaling. Despite established AR antagonists, AR signaling remains a central mechanism of CRPC progression, involving AR gene amplification, reactivation of AR/AR variants, and generation of constitutively active AR-V7 variant. Therefore, there is an urgent need for anticancer drugs that can target these crucial signaling pathways to trigger apoptosis and growth inhibition in CRPC. We have previously shown that the combination treatment of carmustine and selenite effectively induces apoptosis in AR-independent PC-3 cells (Cancer Manag Res. 2012; 4: 383-95) . Since there are no drugs available as of today to inhibit AR/AR variants, we tested whether the combination of carmustine and selenite could induce apoptosis and inhibit growth of CRPC cells (22Rv1) in in vitro and in vivo models and if this response is mediated by targeting AR/AR variants and AR-V7 in tandem with multiple signaling pathways. and normal prostate epithelial cell lines were used to study the efficacy of carmustine and selenite in combination. Anchorage-independent growth of 22Rv1 and PC-3 cells was determined by a soft-agar assay. In vivo antitumor efficacy of the combination agent with therapeutically relevant doses was studied in a 22Rv1 xenograft mouse model. AR/AR variants, PSA and multiple signaling pathway (AKT, anti-apoptotic proteins, Bcl-2 and Mcl-1; cell cycle regulator, p27; and markers of proliferation, c-Myc and cyclin-D1) proteins were determined by western analysis.
Combination of carmustine and selenite treatment completely abolished the protein expression of AR/AR variants, AR-V7, PSA in a time dependent manner, substantially decreased cell viability, growth, and induced apoptosis in 22Rv1 cells. In addition, the combination treatment dramatically induced p-H2AX, p27 while strongly inhibiting pAKT, Bcl-2, Mcl-1, c-Myc and cyclin-D1 in 22Rv1 cells without causing genotoxicity in normal prostate epithelial cells. In addition, anchorage-independent growth of 22Rv1 and PC-3 cells was completely inhibited. Consistent with in vitro results, combination treatment induced apoptosis and eradicated 22Rv1 xenograft tumors in nude mice correlating with dramatic inhibition of AR/AR variants, AR-V7, PSA, and Bcl-2 in xenograft tumors. A significant reduction in toxicity was revealed by an observed decrease in body weight loss. Whereas, individual agent treatment showed only partial effect both in vitro and in vivo. This is the first study to demonstrate that the combination of carmustine and selenite treatment completely inhibits AR/AR variants, AR-V7, and induces apoptosis in CRPC which is highly correlated with tumor growth inhibition in vitro and in-vivo. Our findings indicate that the combination of carmustine and selenite can be the next-generation therapy for successful treatment, survival, and improved quality of life of patients with castration resistant prostate cancer. Mutation of tumor suppressor p53, which exhibits oncogenic gain-of-function (GOF) and promotes tumor progression, emerges as a therapeutic target for approximately 50% of all cancer cases. However, it is still unclear whether it is possible to restore GOF of p53 mutants without heterotetramer effect, as this often eliminates the efficacy of current approaches used to restore p53 function in p53 mutant cancers. Ceramide, an active sphingolipid metabolite, has pro-apoptotic effects on cancer cells but the hydrophobicity it has limits to develop ceramide as therapeutic agents. Here, we report that the ceramide-rubusoside (Cer-RUB), an ultrasmall nanomicelles enhances the bioavailability of C6-ceramide in vivo and restores wild-type p53 expression and its function in tumor suppression. We found that Cer-RUB nanomicelles enhanced the aqueous solubility of ceramide by 2,000-folds (2 mg/ml vs. <1.0 μg/ml), presented mono-disperse with an average particle sizes of 4 nm in cell culture medium, and elongated ceramide activity, due to a decrease in Cer-RUB glycosylation, compared to the C6-ceramide. More interestingly, Cer-RUB treatments (0.6 µM; 1 mg/kg) restored wild-type p53 expression documented in protein levels of phosphor-p53 and p53 responsive genes (p21, Bax) in cancer cell lines carrying R248G and R273H missense mutants and in heterozygous transgenic mice of 129S4-Trp53tm2.1Tyj. Cer-RUB significantly sensitized the resistance of these cells to anticancer drugs and eliminated cancer stem cells in cell culture and in tumor-bearing mice. This study indicates that Cer-RUB is a new approach to effectively target p53 mutant cancers.
Late-Breaking Abstracts
Therapeutic Agents: Small Molecule Kinase Inhibitors
LB-A20
Novel dual oncogenic target inhibitor against allosteric mitogen-activated protein kinase (MEK1) and phosphatidylinositol 3-kinase (PI3K). Brian D. Ross, Hao Hong, Hanxiao Wang, Charles A, Nino, Marcian E. Van Dort. University of Michigan School of Medicine, Ann Arbor, MI.
The Ras/MEK/ERK and PI3K/Akt/mTor pathways play a central role in the regulation of normal cell growth, division and differentiation. Dysregulation of these signaling pathways driven by oncogenic mutations/activation leading to elevated kinase activity has been demonstrated in many human cancers. Strong evidence suggests the existence of a feedback loop with crosstalk between these two signaling cascades leading to redundancy in survival pathways. Consequently, monotherapy targeting a single cascade may be insufficient to induce tumor cell death due to drug resistance mechanisms. Initial biological results are presented from a series of novel small molecule kinase inhibitors specifically designed to simultaneously target both MEK1 and PI3K. Structural analogs of the ATP-competitive PI3K inhibitor ZSTK474 and the ATP-noncompetitive class of MEK inhibitors PD0325901, respectively, were covalently combined to provide single compound dual inhibitors. Inhibitors showed potent MEK1 inhibition (0.015 < IC50 (nM) < 56.7) and PI3K inhibition (54 < IC50 (nM) < 341) in tumor cell culture inhibition assays. Cellular efficacy studies were accomplished and revealed several of the designed inhibitor analogs demonstrated near complete inhibition of MEK1 and PI3K kinase activity by western blot analysis in A549 lung adenocarcinoma and D54 glioma cell lines at concentrations as low as 5 μM. Inhibitors also produced dosedependent decreases in cell viability in these cell lines similar to that displayed with the combined administration of equivalent doses of ZSTK474 and PD0325901. In vivo evaluation of selected compounds was undertaken to evaluate oral bioavailability and activity. In preliminary studies conducted in D54 glioma tumor bearing mice, a 95% and 67% inhibition of tumor ERK1/2 and Akt phosphorylation, respectively, was found at 2 h post-administration as determined by western blot analysis. This study reveals that dual targeted small molecules designed to inhibit MEK1/PI3K pathways were effective in target modulation in intact mouse tumor models. Overall, this study details a highly novel approach for combined MEK1/PI3K inhibition with first in vivo results.
LB-A21
Single-agent activity and favorable pharmaceutical properties of orally bioavailable next-generation CDK4/6 inhibitor, ON 123300. Benjamin Hoffman Introduction: Recent proof-of-concept for targeting cyclin dependent kinases 4 and 6 (CDK4/6) culminated in the approval for breast cancer of the first-in-class CDK4/6 inhibitor, palbociclib (Ibrance®). Palbociclib and other potent but narrowly targeted CDK4/6 inhibitors are cytostatic rather than cytotoxic (Leonard et al, 2012) , and require combination therapy for optimal activity. ON 123300 is a next-generation CDK4/6 inhibitor with improved single-agent cytotoxicity. This novel compound is a potent CDK4 and CDK6 inhibitor (IC50=3.9 nM and 9.8 nM, respectively) that is cytotoxic against breast and other cancer cell lines (Reddy et al, 2014) . We present pre-IND profiling pharmacology, physicochemical and ADME studies to support ON 123300 as a clinical candidate and next-generation CDK4/6 inhibitor.
Methods and Results: Non-clinical studies were conducted in order to assess the drug-like properties of ON 123300 and its pharmaceutical salts. Physicochemical parameters were determined for the compound. ON 123300 was highly soluble below pH 4.0, with reduced solubility in more basic conditions. Predicted intestinal absorption, as measured by Caco-2 permeability, was 1.95x10-5 cm/s with a low efflux ratio. Based on these characteristics, the compound was advanced to lead profiling against 68 primary molecular targets. Radioligand binding studies revealed limited receptor inhibition (11/68 targets) with 10 μM of ON 123300. Human Ether-a-go-go (hERG) inhibition testing revealed no significant effect (IC50 > 25 μM). In vitro metabolism studies indicated metabolism through CYP3A4 and CYP2C8. Finally, in silico based modeling Late-Breaking Abstracts (Cloe® PK) integrating all key non-clinical parameters was carried out in order to estimate the potential for oral absorption in humans. Preliminary analysis suggests good oral bioavailability and the potential to establish an acceptable therapeutic window.
Conclusions: The well differentiated biochemical, anticancer and pharmaceutical properties of ON 123300 provide the basis for pre-clinical toxicology testing, leading to an investigational new drug (IND) filing and clinical exploration of this compound across tumor types that share targets accessed by this nextgeneration CDK inhibitor.
Tumor Microenvironment
LB-A22
Comparison of the effect of pharmaceutical compounds on tumor cells in 2D and 3D in vitro models using label-free, quantitative 4 dimensional holographic imaging. Ed Luther, Giuseppina Salzano, Shravan K. Sriraman, Daniel Costa, Vladimir P. Torchilin. Northeastern University, Boston, MA.
Introduction: Development of in vitro models for the evaluation of drugs represents a useful approach as in vivo studies may be costly and time consuming. Ideal models should take into account the effects of the cellular microenvironment, which includes the extra-cellular matrix, stroma and neighboring cells.
Phase Holographic Imaging
The Holomonitor®M4 (Phase Holographic Imaging, Lund, Sweden) is an incubator-adapted time-lapse holographic imaging cytometry system that enables quantitative, label-free analysis of living cells. A lowpower red laser creates an interference pattern (hologram) which is reconstructed by software into images. Software modules are available for cellular segmentation, calculating quantitative features (optical thickness and volume), and individual cell tracking. Cells were plated in Petri dishes and imaged in 5 minute intervals for 2 to 3 days. The field of view with a 20X objective is 538 μm2 with an effective depth of field in the mm range, allowing monitoring elongated cubes of the tumor microenvironment. We export 2D projections of the holograms into Image J. We then produce 4-dimensional plots of the tumor microenvironment (X and Y position, cell thickness coded as brightness, and time in the Z direction).
2D models of non-motile adherent cells.
When untreated HeLa cells are seeded at low density, colonies manifest as inverted cones increasing in diameter as the cell number increases. Mitotic cells appear as short duration bright spots due to rounding of the cells and increase in optical thickness. Treatment with colchicine at concentrations sufficient to block the completion of mitosis caused the brightness of the tracks is persistent. When treated with doxorubicin (dox) at concentrations sufficient to induce apoptosis, cell tracks briefly become bright, but then decrease in diameter and brightness as the cells gradually disintegrate.
2D models of motile cells.
HT1080 fibroblasts present two distinct morphological types, an amoeboid form that move via extensions of lamellipodia from a leading edge that adhere to a substrate and a mesenchymal form, where small protrusions termed lobopodia propel cells by attaching to ECM components.
In untreated samples, cells are predominately in the amoeboid form, with the cell tracks moving upward. Low concentrations of dox (50nM) abolish cell proliferation, and a shuttling motion is seen, caused by dysfunctional lamellipodia attachment to the substrate prior to eventual cell death.
3D models of motile cells.
We plated HT1080 cells on the dishes, treated them with compounds, and then overlaid the cells with 1 mg/ml collagen type 1.
With 50 nM dox there is a high degree of proliferation and vastly increased planar motion. In videos it can be seen that cells are following pathways created by other cells, consistent with cells burrowing through the ECM.
Conclusion: We developed a novel 4-D holographic imaging method using the Holomonitor HM4 and Image J. Here, we present methods for comparing traditional 2D and 3D in vitro models. Our example of HT1080 cells treated with dox clearly shows the superiority of the 3D model, an important step in developing assays that better emulate multi-dimensional biological processes and offer the possibility of evaluating effects of drugs at lower cost and experimental complexity than those of in vivo assays.
LB-A23
Galectin-8 favors growth of endothelial cells and induces production of extracellular matrix by cancer associated fibroblasts. Peter Gal Galectins (Gal) belong to a family of endogenous lectins specifically recognizing sugar motives and playing an important role in the biology of tissue repair and cancer. It has been shown that the tandem-repeat lectin Gal-8 plays an essential role in tumor angiogenesis by improving endothelial cell migration and capillary tube formation. Interestingly by a more prominent way than the proangiogenic growth factor VEGF. Thus, new question arises, i.e. does Gal-8 improves endothelial cell proliferation? To provide answer to that question the MTT and BrDu proliferation assays using HUVEC (human umbilical vein endothelial cells) as a model were used. We found that Gal-8 induces cell proliferation in combination with VEGF, but Gal-8 alone does not exhibit any significant effect. Furthermore, we studied whether human Gal-8 induces production of a bioactive extracellular matrix (ECM) scaffold by cancer associated fibroblasts (CAF). In parallel, the effect of Gal-8 on ECM production by human dermal fibroblasts (HDF) was studied as well. Adding Gal-8 to the culture medium led the CAF to generate a very fine structured 3D meshwork especially rich in fibronectin. Contrary, the ECM production by HDF was not that apparent. Since ECM-cell interactions play an important role in the ability of tumors to spread and form metastasis further research focused on roles of the tandemrepeat-type Gal-8 in other steps of tumorigenesis is warranted by present in vitro study. This abstract has been withheld from publication due to its inclusion in the AACR-NCI-EORTC Molecular Targets Conference 2015 Official Press Program. It will be posted online at the time of its presentation in a press conference or in a session: 10:00 AM ET Friday, November 6.
LB-A25
PTEN loss promotes phosphorylation-dependent acetylation and inhibition of SPOP tumor suppressor. Jian An, Haojie Huang. Mayo Clinic, Rochester, MN.
The Cullin 3-based E3 ubiquitin ligase substrate-binding protein SPOP is inactivated in approximately 8-15% of human prostate cancers due to gene mutation. Intriguingly, SPOP mutations and inactivation of the PTEN tumor suppressor in human prostate cancers are mutually exclusive. However, it is unclear whether SPOP remains functionally active in PTEN-deficient prostate cancer cells. In the current study, we demonstrate that PTEN loss induces phosphorylation and nuclear exportation of SPOP. We identify a putative cyclindependent kinase (CDK) phosphorylation site (serine 222) in SPOP BTB domain, a motif interacting with Cullin 3 and demonstrate that PTEN loss induces SPOP cytoplasm accumulation in a manner dependent on CDK2-mediated phosphorylation of SPOP at serine 222. We further show that serine 222 phosphorylation impairs dimerization and the E3 ligase activity of SPOP without affecting its interaction with Cullin 3. We also identify a potential p300 acetylation site in the C-terminal nuclear localization sequence of SPOP. We demonstrate that acetylation by p300 promotes SPOP translocation from nucleus to cytoplasm and this effect is enhanced by CDK2-mediated phosphorylation of SPOP at serine 222. In contrast, Sirt 2 and Sirt 6 of the sirtuin family are verified to be responsible for deacetylation of SPOP. In the conditional Pten knockout prostate cancer mouse model, Pten deletion induces cytosolic accumulation of SPOP, but the process is reversed in Pten and p300 double knockout prostatic cells. Collectively, our findings reveal cytoplasmic localization and enzymatic inactivation of SPOP as a previously uncharacterized mechanism that contributes to PTEN loss-induced prostate tumorigenesis. They also suggest that blocking SPOP cytoplasm localization represents a viable therapeutic option for treatment of prostate cancers harboring PTEN inactivation.
Late-Breaking Poster Session B
Saturday, November 7, Background: Most NSCLC patients harboring activating EGFR mutations benefit from treatment with EGFRTKIs, but the final clinical efficacy of EGFR-TKIs varies because of development of tumor resistant to EGFRTKIs. Multiple kinase-targeted 2nd generation TKIs such as afatinib have been developed to overcome drug resistance to the 1st generation TKIs. Afatinib is an irreversible multitargeted TKI targeting EGFR including T790M, HER2 and HER4. To develop further personalized therapeutics and drug resistance modifiers, we should understand the molecular based mechanism of drug resistance to 2nd as well as 3rd generation TKIs. In our present study, we present a novel finding that acquisition of cancer stem-like cells properties accompanying with activation of residual Src family kinase (SFK)/focal adhesion kinase (FAK) is responsible for the survival of afatinib-resistant lung cancer cells when expression of targeted EGFR, HER2 and HER4 is abraded.
Materials and methods: We have established afatinib-resistant subclones from human lung cancer cell lines, HCC827, harboring activating EGFR mutation after stepwise exposure to afatinib. The afatinib-resistant clones do not harbor T790M, K-ras mutation or PTEN loss. We have characterized biochemical properties of drug-resistant subclones as compared with their drug-sensitive counterparts by Western blot and RT-PCR. ALDEFLUOR kit was used to isolate cell populations with the stem cell specific ALDH enzymatic activity.
Results: We characterized two independent afatinib-resistant subclones, BR1-8 and BR2-3.
[1] Afatinibresistant subclones showed markedly decreased expression of EGFR, HER2, HER3, c-Met and PDGFRβ as compared with their parental cell lines, HCC827; [2] Akt phosphorylation in afatinib-resistant subclones was not suppressed by afatinib; [3] SFK and FAK were activated in resistant subclones, and combination of afatinib with c-Src siRNA or with dasatinib moderately suppressed cell growth and AKT phosphorylation; [4] Combination of afatinib with siFAK moderately blocked cell growth of resistant subclones. [5] Cancer stem like cell marker, ALDH1, positive cell population increased in afatinib-resistant sublines compared with HCC827 cell lines.
Conclusions: Together, our present study presents that increase of cancer stem like cells and SFK/FAK activation could be a mechanism responsible for acquired resistance to afatinib. We would further discuss the association of ALDH1 expression and SFK/FAK activation with afatinib resistance in lung cancer.
LB-B03
miR-24 acts as a tumor suppressor and radiosensitizer by targeting Jab1/CSN5 functions. Francois X. Claret Radiotherapy is the standard therapy for head and neck cancer; however, radioresistance can hinder successful treatment and is likely to give rise to local recurrence and distant metastatic relapse. Recent studies revealed the role of microRNA (miRNA)-mRNA mediated regulation in tumorigenesis; however, whether specific miRNAs regulate tumor radioresistance and can be exploited as radiosensitizing agents remains unclear. The purpose of this study was to identify an miRNA signature from differentially expressed miRNAs in radioresistance. Here, we report that miR-24 acts as a tumor suppressor and radiosensitizer in nasopharyngeal carcinoma (NPC) cells and mouse models by targeting Jab1/CSN5 and that loss of miR-24 is highly associated with poor survival. When combined with irradiation, miR-24 acted as a radiosensitizer in NPC cells. Jab1/CSN5 functioned in a manner opposite that of miR-24 in NPC tumorigenesis and radioresistance. We demonstrated that miR-24 inhibits Jab1/CSN5 translation, leading to tumor growth inhibition, and sensitizes NPC tumors to radiation in vivo. Moreover, miR-24 inhibits DNA damage repair by targeting JAB1/CSN5. Finally, comparative analysis of paired samples of primary and matched recurrent NPC tissues showed that miR-24 levels were significantly lower and Jab1/CSN5 levels were higher in recurrent NPC than in primary NPC. Our findings identify miR-24 as a tumor suppressor and radiosensitizer miRNA and reveal a new therapeutic strategy for radioresistant tumors. Tumors are complex and robust biological systems that harbor the potential to proliferate against various drug treatments. Drug combinations provide a promising therapeutic strategy, but it is not clear which and how many drugs are required to overcome cancers.
Using image-based proliferation and apoptosis assays in colorectal cancer cells we systematically investigated complex treatments composed of two to six drugs targeting critical oncogenic pathways. Drug pairs targeting growth signaling resulted in synergies across a broad spectrum of genetic backgrounds, but often yielded cytostatic responses and failed to induce apoptosis. Enhanced, and sometimes genotype-specific cytotoxicity was seen after targeting additional mechanisms including apoptosis or cell cycle. Cells that resisted all tested drug pairs and drug triples were protected by a mechanism that prevented apoptosis. Targeted inhibition of this mechanism using combinations of up to four compounds induced cytotoxic responses in cells in vitro and in vivo.
Our results demonstrate that complex combinations of targeted drugs might be required to induce killing in cancers and show how the cells' genetic alterations and a molecular understanding of drug responses can guide their identification. The identification of resistance mechanisms that are pre-existing in subpopulations of tumor cells also opens the exciting avenue of sequenced treatments, with each drug or drug combination targeting and eradicating a specific cell population. Cetuximab and panitumumab are monoclonal anti-EGFR antibodies (moAbs) currently used for the treatment of 'RAS' wild type colorectal cancers (CRC). Development of acquired resistance almost invariably limits the efficacy of these agents. At relapse, about 20% of tumors treated with cetuximab and panitumumab carry EGFR extracellular domain (ECD) mutations (S492R, R451C, S464L, G465R, G465E, K467T, I491M), which impair antibody binding. We postulated that mCRC patients who become resistant to cetuximab or panitumumab due to the emergence of EGFR ECD mutations may still benefit from further line of treatment with EGFR blockade. We observed that the EGFR ECD variants are effectively targeted by the oligoclonal anti-EGFR antibody MM-151. MM-151 inhibits EGFR signaling and cell growth in preclinical models, including patient-derived cells carrying mutant EGFR.
We have analyzed liquid biopsies of 11 CRC patients that developed resistance to previous treatment with cetuximab and were then enrolled in the first MM-151 phase I study. Longitudinal profiling of circulating cellfree tumor DNA (ctDNA) samples collected during MM-151 treatment revealed a decrease of EGFR ECD mutant levels that paralleled the response as measured by radiological methods.In conclusion, we provide mechanistic evidence for the efficacy and use of MM-151 as a therapeutic opportunity for patients whose tumors develop EGFR ECD mutations as the prevalent mechanism of acquired resistance to cetuximab or panitumumab treatment.
Epigenetic Targets
LB-B06
Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Catherine S. Grasso. Fred Hutchinson Cancer Research Center, Seattle, WA.
Diffuse intrinsic pontine glioma (DIPG) is a fatal childhood cancer that has a limited response to treatment (median survival after diagnosis is only 9 months). Historically, DIPG research has been limited by a dearth of tumor tissue available for study and a lack of experimental model systems. Recently, both cell cultures derived from patients with DIPG and orthotopic xenograft models have been established. We performed a chemical screen in 16 patient-derived DIPG cultures using 83 drugs, selected by pediatric neurooncologists as either promising small-molecule compounds or traditional chemotherapeutic agents. Of these 83 drugs, 14 showed activities against three or more DIPG cultures. Notable 'misses' that highlight the resistance of Late-Breaking Abstracts this tumor to traditional chemotherapies included temozolomide, carboplatin, and vincristine, while DIPG cell cultures were reported to have substantial sensitivity to histone deacetylase inhibitors, consistent with the highly recurrent H3K27M driving mutations in ~80% of DIPG. Panobinostat was one of the most effective drugs screened, with 12/16 DIPG cultures showing sensitivity to this drug. Compared to vorinostat, another HDAC inhibitor, panobinostat exhibited substantially greater potency against DIPG cells. Treatment of DIPG cultures with panobinostat yielded a time and dose-dependent decrease in viability (RNA-mediated knockdown of HDAC1 and HDAC2 confirmed the mechanism of action). Treatment of DIPG cultures with panobinostat also increased H3 acetylation and H3K27 trimethylation, and led to a partial rescue of the H3K27M induced global hypotrimethylation phenotype. Increased K27 trimethylation was an unexpected effect of the drug, but it is consistent with recent findings that acetylated H3K27 can 'detoxify' K27M-induced inhibition of PCR2. RNA-seq performed on panobinostat-or vehicle-treated DIPG cells revealed sweeping changes in gene expression, including normalization of the K27M gene expression signature and decrease of the oncogenic MYC target gene-expression signature. In addition, the multi-histone deacetylase inhibitor panobinostat demonstrated efficacy in DIPG orthotopic xenograft models administered using convection enhanced delivery. Combination testing of panobinostat and the histone demethylase inhibitor GSK-J4, recently shown to decrease viability of mutant DIPG cells, revealed that the two had synergistic effects. Together, these data suggest a promising FDA-approved therapeutic strategy for DIPG that could be rapidly translated for use in the clinic, further indicating that epigenetic modifying therapies are emerging as the most promising class of agents for the treatment of DIPG.
Genomics, Proteomics, and Target Discovery LB-B07
MiSL: A method for mining synthetic lethal partners of somatic mutations identifies acetyl-CoA carboxylase as a synthetic lethal interactor of the IDH1 mutation in leukemia. Subarna Sinha Synthetic lethality, in which a single gene defect leads to dependency on a second gene that is otherwise not essential, is an attractive paradigm to identify targeted therapies for cancer-specific mutations. Current methods to detect synthetic lethal (SL) partners for somatic mutations rely on large-scale shRNA screens in cell-lines or use human orthologs of yeast SL interactions, both of which are not necessarily representative of primary tumors and have incomplete coverage.
We have developed MiSL, a novel Boolean implication-based algorithm that utilizes large pan-cancer patient datasets (mutation, copy number and gene expression) to identify SL partners for cancer mutations. The underlying assumption of our approach is that, across multiple cancers, SL partners of a mutation will be amplified more frequently or deleted less frequently, with concordant changes in expression, in primary tumor samples harboring the mutation. Pan-cancer analysis discovers robust biological relationships that are likely to be independent of cancer subtype and increases statistical power.
First, we sought to validate MiSL using existing knowledge and large-scale shRNA data. Consistent with prior knowledge, MiSL candidates for BRCA1 mutation (mut) in breast cancer were enriched for DNA repair genes (p=.0.006). We also found: (1) significant overlap (p=0.002) between leukemia IDH1mut MiSL candidates and essential genes in IDH1mut cells determined by a DECIPHER shRNA screen we performed in doxycycline-inducible IDH1 (R132) THP-1 cells, and (2) for multiple mutations in colorectal cancer, MiSL candidates were enriched (p<0.05) with genes that were selectively essential in mutated colorectal cell-lines in Achilles data.
Next, we experimentally confirmed novel SL partners that are druggable in (i) acute myeloid leukemia (AML) and (ii) breast cancer. We tested the response to 17 drugs whose targets were predicted to be SL Late-Breaking Abstracts partners of IDH1mut in AML by MiSL. For a majority of these drugs, treatment with the drug reduced cell viability selectively in the presence of the mutation in AML cell-lines, suggesting that the MiSL identifies true SL partners. Importantly, MiSL predicted a novel SL interaction in AML between IDH1mut and ACACA, the rate-limiting enzyme that controls lipid biosynthesis. Consistent with our prediction, selective inhibition of ACACA with shRNA or a small molecule inhibitor TOFA prevented cell proliferation in the presence of IDH1mut but not with IDH1 wildtype in AML cell-lines and primary blasts (n=5/6 IDH1mut/IDH1 wt, p=0.04). This suggests a novel role for IDH1mut in reprogramming lipid metabolism. MiSL also predicted that AKT1 is a SL partner of PIK3CAmut in breast cancer which we experimentally confirmed using 8 breast cancer lines. All four PIK3CAmut (but not wildtype) breast cancers were sensitive to AKT1 inhibition in viability and colony assays.
In conclusion, MiSL is a general computational solution that finds novel SL interactions and its use can greatly accelerate novel target discovery for precision medicine in cancer. Using primary patient data allows it to capture in vivo tumor evolution in the human microenvironment, revealing SL interactions missed by existing methods. It can be widely applicable and can greatly accelerate novel target discovery for precision medicine in cancer.
LB-B08
Somatic mutation detection from liquid biopsy-derived cellular aggregates formed by magnetic 3D bioprinting. Hubert Tseng Background: A challenge in the analysis of circulating tumor cells (CTCs) is their scarcity and the inability to expand them for further analysis. To overcome this obstacle, we used magnetic 3D bioprinting to form CTC spheroids that could grow. The principle of magnetic 3D bioprinting is the magnetization of cells with nanoparticles and their subsequent printing into spheroids. For this project, CTCs were aggregated into close contact to facilitate interactions and growth in culture. We then demonstrated the ability to perform next generation sequencing (NGS) of the spheroids to detect somatic mutations from renal and prostate cancers.
Methods: Blood samples from prostate and kidney cancer patients were enriched for CTCs (Isoflux, Fluxion Biosciences), from a starting blood volume of 7.5-14 mL. CTCs were isolated immunomagnetically for EpCAM+ EGFR+ cells, then enumerated for CK+ CD45-. The cells were then magnetized by incubation with NanoShuttle (NS, Nano3D Biosciences) and printed into spheroids in 384-well plates. After 4 d of growth, the cells were lysed and DNA was amplified by whole genome amplification (WGA) with the NGA kit (Fluxion Biosciences) and quantified via qPCR. Targeted libraries were sequenced using the PGM (ThermoFisher) sequencing instrument; data was analyzed using a customized variant calling/filtering pipeline based on standard Ion Reporter alignment tools and VarSeqTM for variant filtering and functional interpretation.
Results: CTCs were successfully aggregated using magnetic 3D bioprinting and grew over 4 d. For both prostate and renal cancers, we then demonstrated the detection of somatic variants within a majority of the samples. Using the commercial Oncomine® test kits (ThermoFisher), we found a median of 5 COSMIC variants (32 total) per sample using cell cultures.
Conclusions: We successfully developed a method to aggregate CTCs using magnetic 3D bioprinting, expanded them, and then identified somatic mutations using NGS. This procedure may form the basis of a liquid biopsy-derived molecular testing platform for monitoring urological tumor progression and planning treatment strategies.
LB-B09
Somatic mutation detection via sequencing using circulating tumor cell samples from patients with renal cell and prostate cancer. Robert J. Amato Introduction: Tumor genotyping using fluid samples such as blood can potentially allow tracking of dynamic changes in mutational profiles over time and allow better access than biopsies. We present a method to detect somatic mutations from a blood draw, where circulating tumor cell (CTC) enrichment above 10% of total cell numbers allows the use of standard gene panels typically used to analyze tissue-based biopsies.
Methods: Clinical samples were obtained from 9 prostate cancer (PC) patients and 6 renal cell cancer (RCC) patients, followed by CTC enrichment using the IsoFluxTM System. Cells were lysed and DNA amplified by whole genome amplification (WGA) using the NGS Kit (Fluxion Biosciences) and quantified via qPCR. CTCs defined as CK+, CD45-nucleated cells (DAPI+) for cell enumeration. Analytical samples were prepare by spiking tumor derived cell lines into whole blood and parallel analysis. Next-generation sequencing was performed using 3 targeted cancer panels on the Ion torrentTM PGM platform: the Ion ampliseqTM cancer hot spot panel (50 genes; 6 PC samples), Oncomine (143 genes; 3 PC samples), and a 29-gene panel of actionable mutations in RCC (6 samples). Data was analyzed using a customized variant calling/filtering pipeline. Variant filtering and functional interpretation was performed using VarSeqTM. All data was analyzed in a blinded manner. Results: Our method was able to isolate CTCs from all patient samples. WGA DNA concentrations were at a range of 25-164 ng/µL (median, 69) in PC and 29-180 ng/µL (median, 69) in RCC. CTC purity after the first enrichment step was in 2.9-33.7% (median, 10.5%) of PC samples and 1.9-33% (median, 14.5%) of RCC ; final CTC purity is estimated at 5-40%. We found 1 variant/sample using hotpot, 12/sample using Oncomine, and 3/sample using the RCC panel.
Conclusions: Our assay consistently detected somatic variants from blood draw using standard gene panels in both PC and RCC. Obtaining repeat tumor biopsies from patients during treatment and/or at time of progression is both challenging and impractical from a clinical perspective. Our assay provides molecular characterization using standard blood draws and will be prospectively validated in clinical trials.
LB-B10
Chemical proteomic analysis of BTK and PI3K using chloroalkane-derivatized small molecule inhibitors. Victoria Pham Chemical proteomics is a rapidly evolving technology that allows for drug target identification for small molecule inhibitors. Here we present an approach utilizing a chloroalkane (CA) moiety capture handle, which can be chemically attached to small molecules and used to pull-down protein binding partners using the HaloTag technology. CA-modified compounds are cell permeable and have minimal impact on potency, allowing for phenotypic assays of the derivatized compound to be recapitulated.
Here we present a study looking at the targets of two compounds -a Brutons Tyrosine Kinase (BTK) small molecule inhibitor and a Phospho-inositol 3 Kinase (PI3K) small molecule inhibitor. BTK is a non-receptor tyrosine kinase expressed in most hematopoietic cells except T cells, it is essential for B cell receptor (BCR) signaling in B cells and as such is the therapeutic focus in many autoimmune diseases, including rheumatoid arthritis (RA) and lupus. Upon binding to growth factor receptor, PI3K is activated which initiates a signaling cascade involving AKT and mTOR that promotes cell cycle progression and cell proliferation. Mutations of the catalytic subunit of PI3KA are observed in several types of cancers. Inhibition of PI3K is therefore an important therapeutic focus.
Taselisib, a selective inhibitor of PIK3CA, and G02599124, an inhibitor of BTK, were derivitized with the CA linker. Phenotypic screens compared to the parental compound showed comparable IC50 values. Both CAcompounds showed good binding to HaloTag and were cell permeable in a U2OS stable cell line. Control and test experiments were performed with BTK-CA compound using Jurkat (T cells) and Ramos (B cells) cell lines. Taselib-CA was studied after 1h and 8h treatment in the HCC1954 cell line. Cells were lysed and the CA compounds, together with the bound targets, were rapidly captured onto magnetic resin coated with HaloTag. Unmodified compound was used to competitively elute interacting proteins. Eluted proteins were processed using SDS-PAGE and in-gel digestion. Peptides were analyzed using nanoscale LC-MS/MS coupled with an Orbitrap Velos Pro mass spectrometer.
Using this approach we were able to specifically isolate BTK when compared to control experiments in T cells. In the Taselib-CA experiment, we were able to specifically isolate the PIK3CA catalytic subunit and PIK3R1 and PIK3R2 regulatory subunits. Observation of the wild type and mutant forms of PI3KCA will be discussed. Treatment of human epidermal growth factor receptor 2 (HER2)-driven breast cancer with the HERtargeting tyrosine kinase inhibitor lapatinib can lead to a rapid compensatory increase in expression, signaling activity and relocalization of HER3 to the plasma membrane, which may attenuate the response to lapatinib. This might imply a potential role for a more dynamic assessment of HER3 tumor status using molecular imaging techniques, such as positron emission tomography (PET), instead of immunohistochemical HER3 staining on tumor biopsies. Here, we explored the feasibility of a dynamic assessment of HER3 status during lapatinib treatment in human breast cancer xenografts using zirconium-89 labeled anti-human HER3 monoclonal antibody (mAb) as a potential tracer for animal PET imaging.
The anti-human HER3 mouse mAb MAB3481 was used for all experiments. The effect of lapatinib treatment on HER3 expression and HER3 mAb internalization in human breast cancer cell lines SKBR3 and BT474 was determined using flow cytometry. Biodistribution was performed using 89Zr-anti-HER3 mAb in mice bearing BT474 or SKBR3 tumors. Mice received daily vehicle or a lapatinib dose of 25, 50 or 100 mg/kg orally. A tracer dose of 89Zr-anti-HER3 mAb combined with the aspecific tracer 111In-IgG was injected 3 days after treatment. Ex vivo organ distribution assessment of 89Zr-anti-HER3 mAb was performed 6 days after tracer injection. Ex vivo tumor analysis using western blotting, ELISA and immunohistochemistry were performed to measure HER3 levels.
In vitro, lapatinib treatment resulted in a ~2-fold increase in membranous HER3 expression and HER3 internalization in SKBR3 and BT474 tumor cells. 89Zr-anti-HER3 mAb tumor uptake was significantly higher compared to 111In-IgG uptake in BT474 (P < 0.01), demonstrating HER3 specific tumor uptake. SKBR3 xenografts did not show HER3 specific uptake, which was likely caused by the poor viability of the tumors. HER3 upregulation was observed in BT474 xenografts after lapatinib treatment for 9 days. The enhanced HER3 expression was related to a 76 ± 9 % increase in 89Zr-anti-HER3 mAb tumor uptake at 25 mg/kg and 92 ± 27 % at 50 mg/kg lapatinib. Lapatinib at the highest concentration (100 mg/kg) strongly inhibited tumor growth and did not increase tumor uptake of the tracer.
In conclusion, HER3-specific uptake of 89Zr-anti-HER3 mAb was shown in breast cancer xenografts. HER3 upregulation after lapatinib treatment was related to an enhanced 89Zr-anti-HER3 mAb uptake in these Late-Breaking Abstracts xenografts. These promising data warrant future dynamic assessment of HER3 status with 89Zr-anti-HER3 mAb PET imaging.
Immune Checkpoints
LB-B12
Using MiXeno mouse models as robust tool to evaluate T cell dependent immunotherapies. Juan Zhang, Meng Qiao, Qian Shi. Crown Bioscience, Inc., Taicang, China.
Backgrounds: Fighting cancer by taking advantage of a patient's own immune system is showing considerable success in oncology research. Using therapeutic antibodies against tumor-associated antigens or modulating the host immune system, has been shown to prolong survival of patients with certain solid tumors or leukemia, particularly when combined with conventional treatments. Recent fast-track designations and regulatory approvals (including the first FDA approvals of anti-PD-1 agents in advanced melanoma) have signified the coming of age of cancer immunotherapy as a treatment paradigm, creating both potential patient benefits and commercial success for the pharmaceutical industry. A lack of experimental immunotherapy models is a major obstacle toward answering these questions and developing better treatments, and there is a high unmet need for new preclinical models to help drive forward immune therapy research and to recapitulate clinical treatments.
Results: Crown Bioscience has created transient human immunity in mice (MiXeno) for testing human immunotherapeutics, particularly T cell engaged immunotherapies by mixing human peripheral blood mononucleated cells (PBMC) with xenograft models. Our data showed that anti-human PD-1 or PD-L1 antibodies demonstrated significant anti-tumor activities in several Mixeno models, including A375 melanoma model and KARPAS-299 lymphoma model. The emergence of the efficacy coincided with the T cell reconstitution in mouse blood. T cells are also recruited to the tumor microenvironment. The number of T cells in the tumor microenvironment varies significant and is largely dependent on tumor cells itself.
Conclusion:
The MiXeno model provides an alternative to the full stem cell reconstitution approach, and may allow T cell engaged immunotherapies (monotherapies or combinational therapies) to be evaluated in xenograft models.
Immune Mechanisms Invoked by Radiation Therapy
LB-B13
The application of high-dose low fraction image-guided irradiation (IGMI) in combination with anti-CTLA4 immunotherapy results in an additive inhibition of tumor growth in syngeneic tumor models. Andrew Introduction: Radiotherapy (RT) is used across multiple cancer types in a number of clinical settings. The primary mechanism of action is thought to be through irreversible damage to tumor cell or associated stromal DNA, but there is an increasing body of evidence that irradiation also mobilizes tumor-specific immunity.
Recent advances in RT with stereotactic and image-guided micro-irradiation (IGMI) have resulted in an increase in tumor specific targeting with a corresponding reduction in associated side-effects. The resultant use of high-dose, reduced fraction dosing regimens (hypofractionation) has resulted in improved clinical response. However, IGMI in the preclinical setting is less common and typically studies utilize whole body irradiation with lead shielding or simple single beam techniques to focus the radiation. Here we report the application of high-dose, low fraction IGMI to demonstrate an additive combination outcome of radiotherapy and immunotherapy and an abscopal effect in a preclinical model. Experimental Procedures: CT26 mouse colon and bioluminescent 4T1 mammary carcinoma cells were implanted subcutaneously into BALB/c mice. Subcutaneous tumor growth was monitored by caliper measurement and bioluminescent imaging (BLI) was carried out to confirm metastatic 4T1 lung tumors. Tumors ( ~100-200mm3) were treated with hypofractionated IGMI, anti-CTLA4 therapy or a combination of both. For IGMI, mice were anaesthetized and CBCT images were acquired using the small animal research platform (SARRP; Xstrahl Ltd). Fractionated irradiation (5 x 6Gy) was administered to the isocenter of the tumor using a multi beam approach to spare the surrounding tissue. Bodyweight and clinical signs were monitored daily. At termination the primary and metastatic lung (4T1) tumors were collected and assessed for immune cell infiltration by FACs.
Results: Response to the hypofractionated IGMI regimen and anti-CTLA4 either alone or in combination was well tolerated with no adverse effects or significant body weight-loss. Monotherapy with anti-CTLA4 exerted no statistically significant effect on primary or metastatic (4T1) tumor growth and treatment with RT resulted in a modest primary tumor growth inhibition (TGI; 40%). When the two treatments were combined, TGI increased (60%) which was statistically significant compared to RT monotherapy, indicating an additive effect. Additionally, there was a decrease in normalized lung cell counts following combination treatment (4T1) indicating an abscopal response on the lung metastases. This decrease in lung tumor burden corresponded to an increase in both the CD8+ T-cells and the ratio of Teff:Treg in the lung samples.
Conclusions: Hypofractionated IGMI when combined with anti-CTLA4 treatment had minimal side effects and showed statistically significant additive reduction in primary tumor growth. Furthermore, combination treatment resulted in a reduced metastatic lung burden indicating an abscopal effect that appears to be driven by an increase in CD8+ T-cells. The SARRP platform enables clinically relevant radiotherapy regimens to preclinical models facilitating improved evaluation of combinations strategies with immunotherapeutics and progression to the clinic.
Immune Modulators
LB-B14
Characterization of next-generation IDO1 and TDO inhibitors as novel cancer immunotherapeutic agents. Barry E. McGuinness, Phillip M. Cowley, Alan Wise, Thomas J. Brown. IOmet Pharma Ltd, Edinburgh, United Kingdom.
Introduction: The enzymes indoleamine 2,3-dioxygenase (IDO1) and tryptophan 2,3-dioxygenase (TDO) catalyse oxidation of the essential amino acid tryptophan (Trp) leading to the formation of immunosuppressive kynurenine (Kyn) pathway metabolites that dampen the immune response in the tumor microenvironment. Both IDO1 and TDO have been shown to be up-regulated in a variety of cancers and blockade of their activity has been shown to stimulate the anti-tumor immune response in pre-clinical animal models. We have discovered and optimized multiple novel chemical series of both highly selective and dual-acting inhibitors of IDO1 and TDO. Herein we describe the in vitro and in vivo characterization of molecules that we are progressing into the clinic.
Methods: In vitro assays measured the effects of IDO1/TDO inhibitors on Kyn production in cancer cells, hPBMCs and effects on T-cell proliferation in co-culture systems. In vitro ADME properties and in vivo PK/PD profiles were measured by standard methods. In the LPS model of Kyn stimulation, LPS was administered at 0.75-3 mg/kg IP simultaneously with oral administration of IDO1 inhibitors. Plasma and tissue samples were collected 20 hours after dosing. In the PAN02 model of tumor growth compounds were orally administered at 100 mg/kg BID once a mean tumor volume of 90 mm3 was reached.
Results: We have characterized the IDO1 and TDO-selective inhibitors and dual-acting inhibitors which demonstrate nM potencies. In IFNγ-stimulated A172 glioblastoma cells expressing both enzymes, the dualacting molecules fully inhibit Kyn production, whilst selective inhibitors yield only a partial response, demonstrating the utility of dual enzyme blockade in cancer cells. The compounds also relieve inhibition of T-cell proliferation in cancer cell/T-cell co-culture assays and demonstrate highly favourable physicochemical and pharmacokinetic properties. These properties translate to superior PK/PD effects following oral dosing in rodents with profound and sustained modulation of plasma Kyn and Trp levels compared to existing clinical molecules. In a mouse model of LPS-induced IDO1 activation, our highly selective IDO1 inhibitors fully ablate the elevation of Kyn in both plasma and lung in a dose-dependent manner. This lung Kyn modulation is more potent and efficacious than that observed for an IDO1 inhibitor currently in clinical trials. In addition, the IOmet IDO1 inhibitors provide superior tumor growth control in a PAN02 syngeneic model.
Conclusions:
We describe the characterisation of novel potent, selective and dual-acting IDO1 and TDO inhibitors. The drug-like properties of these candidate-quality molecules translate to superior rodent in vivo PK/PD and anti-tumor profiles compared to compounds in clinical trials. This clear advantage is expected to translate to a significantly better PK/PD effect in humans, especially in lung cancer -a major opportunity for α-PD-1/PD-L1 and IDO1 inhibitor combination therapy.
LB-B15
A novel PI3K gamma isoform selective small molecule kinase inhibitor demonstrates single agent anti-tumor activity and enhanced combination activity with checkpoint blockade in syngeneic mouse models of cancer. Saurabh Saha Immunotherapy is emerging as one of the most promising approaches in cancer treatment, allowing specific targeting of cancer cells from CD8+ T Lymphocytes based on surface marker expression. In vitro characterization of the efficacy and potency of BiTEs or CAR T-Cell constructs is a necessary step before moving to animal models and Phase I and II clinical studies. In this study we present the optimization of several protocols to analyze cancer immunotherapy reagents using an impedance-based platform. The platform allows detection of cell adhesion and cell death trough monitoring the change in conductance of microelectrodes embedded on the bottom of the culture dish. Because cell adhesion over the electrodes alters the conductivity of the surface, any change in cell morphology, adhesion or number is detected as alteration of an impedance-related parameter called Cell index (Ci). Furthermore, because the platform avoid the use of any chemical label or sample processing, it allows continuous monitoring of cell activity. Dose-responses curves of BiTEs antibodies against epithelial tumor cell lines with a range of expression of the EpCAM antigen show correlation between surface expression level and efficacy of the constructs. Decreasing ratios between effector and target cells, in combination with longer time of monitoring reveal the efficacy of such constructs also at equivalent stoichiometric ratio. Taken together our results demonstrate higher sensitivity of the impedance-based approach over established methodologies like Chromium-51 release assay and live-cell imaging, improving and speeding up the workflow for therapy optimization.
Metastasis and Invasion
LB-B18
Epithelial to mesenchymal transition in human tumor biopsies: Quantitative, histopathological proof of the existence of EMT in vivo by immunofluorescence microscopy. Tony Navas Epithelial-mesenchymal transition (EMT) is a dynamic process whereby epithelial cells acquire mesenchymal properties. Despite the clinical significance of the acquired mesenchymal properties for metastasis and drug resistance, histopathological evidence of transitional cells in patient samples is lacking and EMT remains an unproven clinical hypothesis. We previously developed and validated a multiplex immunofluorescence assay (IFA) that quantifies the levels of EMT biomarkers (E-Cadherin, Vimentin, β-catenin) in snap-frozen, formalin-fixed, paraffin-embedded (FFPE) tumor tissue (Navas et al, AACR 2013) . Building upon that method, we now report a precise, quantitative and unbiased IFA method of tissue analysis (EMT-IFA) using Definiens® software to quantify co-expression of the epithelial marker E-cadherin (E) and mesenchymal marker Vimentin (V) at the cellular level in FFPE clinical biopsies. FFPE human tumor xenografts and cell lines serve as calibrators and reference materials for establishing initial image acquisition parameters for segmented tumor regions of interest. Flanking H&E sections of the clinical biopsies are initially annotated by an anatomic pathologist to identify regions of tumor tissue, non-tumor related areas (including normal or stromal tissues), inflammatory and/or necrotic regions, and freeze artifacts. Adjacent sections are used for the EMT-IFA, and further tumor segmentation from stroma is applied to extracted regions of interests (fields) using the β-catenin layer. Within segmented tumor regions, E-cadherin (E) and Vimentin (V) subcellular pixel areas are measured using predetermined thresholds for each biomarker and reported as Log10 (V:E ). High resolution images confirmed the co-localization of plasma membrane E-cadherin and cytoplasmic Vimentin to individual transitional tumor cells, and the co-localization of E and V within individual tumor cells of the segmented regions of interest was key for distinguishing EMT from tumor heterogeneity in which adjacent tumor cells can be exclusively E+ or V+. Quantitative analysis of a clinical biopsy series of various histologies revealed all possible phenotypes: epithelial (E+V-colorectal carcinoma), mesenchymal (E-V+ sarcomas), heterogeneous mixtures of E+V-and E-V+ subpopulations, and EMT. Importantly, using the EMT-IFA, we discovered that pharmacological targeting of VEGFR/FGFR/PDGFR signaling with the multi-kinase inhibitor pazopanib stimulated EMT in a preclinical xenograft model of gastric carcinoma (MKN45), as revealed by the significant increase in the V:E ratio (P=0.0023) coupled with an increase in the EMT phenotype (co-localized V+E+ at the individual cell level) (P=0.0070) in biopsy specimens. Thus, the EMT-IFA has potential value for investigating EMT in the clinic and its ramifications for drug response and other clinical endpoints. Funded by NCI Contract No. HHSN261200800001E.
LB-B19
BKM-120: A phosphatidyl-inositol-3 kinase inhibitor with anti-migratory properties in glioblastoma. Maria Carmela Speranza, Michal O. Nowicki, Choi-Fong Cho, E. Antonio Chiocca, Sean E. Lawler. Harvard Medical School -Brigham and Women's Hospital, Boston, MA.
Glioblastoma (GBM) is the most common glial brain tumor and is also one of the most lethal human cancers: patients have a median survival of 15 months with a five-year survival rate of only 3%. The current standardof-care has remained the same for the last decade and consists of maximal safe surgical resection followed by radio-and chemotherapy. GBM cells are highly infiltrative, leading to invasion of normal brain tissue by tumor cells. These invasive tumor cells render GBM a surgically incurable disease and tumor recurrence is almost inevitable, with 90% of patients developing new lesions within 2-3 cm of the original site or at distant sites in the brain. Moreover, invasion may increase further during anti-angiogenic therapy with bevacizumab and no anti-invasive approaches are yet available clinically.
The phosphatidyl-inositol-3 kinase (PI3K) pathway is frequently deregulated in cancer and is activated in the majority of GBM cases due to constitutive receptor tyrosine kinase activation as well as inactivating mutations/deletions of PTEN (33%) or activating PI3K mutations (17%). In addition PI3K plays a role in cell migration in some cell types and a number of small molecule PI3K inhibitors are under investigation in oncology clinical trials.
BKM-120 (Buparlisib), is a CNS-penetrant selective pan-class I phosphatidyl-inositol-3 kinase (PI3K) inhibitor in clinical trials for several types of solid tumor, including GBM. We initially observed that BKM-120 is a potent anti-invasive molecule in GBM cell lines and patient-derived glioma stem-like cells in vitro. The antimigratory effects of BKM-120 were clearly distinguishable from cytostatic and cytotoxic effects that occurred at higher drug concentrations and after a longer duration of drug exposure. The blockade of migration was reversible and accompanied by changes in cell morphology and pronounced reduction in both cell/cell and cell/substrate adhesion. In vivo studies showed that a short period of treatment with BKM-120 slowed tumor spread in an intracranial xenograft model. Mechanistically we found that GDC-0941, a similar potent and selective PI3K inhibitor, only caused a moderate reduction in glioblastoma cell migration. The effects of BKM-120 and GDC-0941 were indistinguishable by in vitro kinase selectivity screening and phospho-protein arrays. However, BKM-120 substantially reduced the numbers of focal adhesions and the velocity of microtubule treadmilling compared with GDC-0941, suggesting that mechanisms in addition to PI3K inhibition may contribute to the anti-invasive effects of BKM-120.
Overall, our data suggest that the CNS-penetrant PI3K inhibitor BKM-120 may be a useful anti-migratory drug for the treatment of highly invasive tumors such as glioblastoma.
LB-B20
Characterization and enumeration of multiple circulating tumor cell phenotypes using two distinct platforms establishes presence of epithelial-mesenchymal transition CTCs in patients. Lihua Wang We are employing a "liquid biopsy" approach for monitoring drug responses to new anti-cancer agents in early stage clinical trials by measuring drug effects in circulating tumor cells (CTCs), which requires the capability to capture and characterize CTCs from patients with diverse diseases including sarcomas, lymphomas and carcinomas. We have been applying the Apostream platform (DEP-FFF separation) with fluorescence imaging and have recently added the 5-channel CellSearch system (MAb coated ferrofluid) for specimen analysis. Use of both CD146 and EpCam capture per specimen, with addition of vimentin and the tumor markers, significantly increased the number of CTCs captured with the 5 channel CellSearch®. A "homebrew" CTC kit was developed that captures circulating cells that are either EpCAM or CD146 marker positive, and it was capable of identifying high numbers of EMT+ tumor marker+ double positive cells in patient specimens. There was statistical equivalency of events flagged as CTCs (CD45-/EpCam+/CK+) in patient specimens analyzed using Apostream or 5-Color CellSearch versus 4-channel CellSearch and 100% concordance between the CellSearch platforms. Reproducibility, as assessed by image re-analysis using Definiens software, was also high (>90%). Tumor marker specificity was established by analyzing normal donor blood, which varied from zero to 2 cells per ml blood depending on the marker set employed (only CD45 negative cells assessed). This approach solves a major limitation of using CTCs to monitor pharmacodynamic response by enumerating statistically significant cell numbers from patients with solid tumors of diverse histologies. Strikingly, both platforms demonstrated the presence of high numbers of CTCs with the EpithelialMesenchymal Transition (EMT) phenotype (10-100 cells per ml in Phase 1 trial populations), and widely used tumor markers such as MUC1, CEA, TLE1, or proteins generated by recombination events such as ASPL-TFE3. The presence of large numbers of CTCs expressing the EMT phenotype may be related to the intensive prior treatment (>3 prior therapies, median) of our phase 1 population.
Funded by NCI contract # HHSN261200800001E.
LB-B21
BI-69A11 inhibits epithelial to mesenchymal transition exploiting β-catenin pathway in colon carcinoma. Ipsita Pal, Mahitosh Mandal. Indian Inst. of Technology Kharagpur, Kharagpur, India.
EMT is a potential biological phenomena required for metastatic dissemination. Although targeting EMT for therapeutic implication has been gaining interest to the scientific community, only few molecules have succeeded to employ their anti-metastatic effect so far. BI-69A11 has been earlier proved for its anti-tumor activity in prostate and colon carcinoma. This study aims to elucidate the biological consequence of BI-69A11 on EMT in colon carcinoma in vitro and in vivo. Our findings showed that BI-69A11 increased epithelial signature marker E-cadherin and reciprocally decreased the mesenchymal markers snail, slug and vimentin. Moreover, cellular migration, invasion and adhesion were potentially hampered by BI-69A11 through β-catenin dependent pathway. The underlying molecular mechanism behind BI-69A11 induced inhibition of EMT includes suppression of nuclear transport of β-catenin, diminished phosphorylation of β-catenin accompanied with enhanced E-cadherin-β-catenin complex formation at the membrane. Moreover, BI-69A11 controlled the transcriptional activity and reversed nuclear translocation by decrease in the phosphorylation at ser552 and ser45/Thr41 residue. The growing interaction between E-cadherin and β-catenin complex also promoted the E-cadherin transcription leading to the reversal of EMT. BI-69A11 caused increasing accumulation of vinculin in the membrane that in turn strengthened the focal adhesion junction leading to the inhibition of metastasis. Overall, these evidences present a thoughtful insight towards underlying molecular mechanism of BI-69A11 induced reversal of EMT in colorecteal carcinoma in vitro and in vivo.
LB-B22
CCNY2 promotes lung cancer cell migration and invasion via regulating F-actin expression. xiaoting zhao, Mei Jiang, wentao Yue. Beijing Tuberculosis and Thoracic Tumor Research Institute/Beijing Chest Hospital, Beijing, China.
Background: Cyclin Y (CCNY) is a novel cyclin and is highly conserved in metazoan species. Cyclin Y mRNA has several transcripts and only ccny1 and ccny2 has been documented. A potential CDK partner of Cyclin Y is PFTAIRE kinase (PFTK1). In hepatocellular carcinoma, cell motility and invasion was enhanced by PFTK1 expression. But the function of CCNY1 and CCNY2 on cell migration and invasiveness has not been reported yet. Methods: Recombined plasmids carrying CCNY1 and CCNY2 were constructed and transfected to H1299 cells to obtain CCNY up-regulation cells. A lentivirus-based RNAi delivery system was used to inhibit CCNY mRNA expression. The role of CCNY in cell motility and invasion was investigated using wound healing and transwell assay. The protein levels in lung cancer cells were determined by western-blot, immunofluorescence technique and high-content cell analysis. Mouse xenograft experiments were carried out to study the metastasis ability of CCNY1 and CCNY2 in vivo. Immunohistochemistry was used to detect the CCNY protein level of lung cancer tissues. Results: cell motility and invasion activity were inhibited and MET (Mesenchymal -Epithelial Transition) was caused by down-regulating of CCNY in 95D and H1299 cells. CCNY2 could enhance cell migration and invasion activity in vivo and vitro. The F-actin level was regulated by CCNY2 expression. In non-small cell lung cancer tissues, CCNY2 was highly expressed and the CCNY2 expression was associated with histological grade. Conclusion: CCNY2 was firstly detected in lung cancer cells and non-small cell lung cancer tissues. Our findings demonstrated CCNY2 not CCNY1 promoted cell motility and invasion by regulating the expression of F-actin and modulating intracellular cytoskeletal components.
Molecular Classification of Tumors
LB-B23
Medulloblastoma regulatory circuitries reveal subgroup-specific cellular origins. Charles Y. Lin Medulloblastoma is a highly malignant paediatric brain tumour, often inflicting devastating consequences on the developing child. Genomic studies have revealed four distinct molecular subgroups with divergent biology and clinical behaviour. An understanding of the regulatory circuitry governing the transcriptional landscapes of medulloblastoma subgroups, and how this relates to their respective developmental origins, is currently lacking. Using H3K27ac and BRD4 ChIP-Seq, coupled with tissue-matched DNA methylation and transcriptome data, we describe the active cis-regulatory landscape across 28 primary medulloblastoma specimens. Analysis of differentially regulated enhancers and super-enhancers reinforced inter-subgroup heterogeneity and revealed novel, clinically relevant insights into medulloblastoma biology. Computational reconstruction of core regulatory circuitry identified a master set of transcription factors responsible for subgroup divergence that validated by ChIP-Seq and implicated candidate cells-of-origin for Group 4. Our integrated analysis of cis-regulatory elements in a large series of primary tumour samples reveals insights into cis-regulatory architecture, unrecognized dependencies, and cellular origins.
LB-B24
Identification of the functional significance of mutations using the novel Precision Cancer Analysis System. Gabi Tarcic Mounting evidence indicates that growth of pathologically identical cancers in each individual patient is fueled by different sets of driving mutations. The need to identify these drivers stems from the recognized necessity for tailoring therapy and scheduling future surveillance. This personalized medical approach has been shown to result in better treatment outcomes. We present a novel Precision Cancer Analysis system (PCAS) capable of identifying activated signaling pathways by means of a transfected cell-based fluorescent reporter assay yielding a quantitative output of particular pathway activation levels. Being a functional platform PCAS reveals activated pathways regardless of the type of mutation behind it, i.e. whether it is already a known mutation or a variant of unknown significance (VUS) mutation. 20 cancer patients were sequenced for a panel of 37 genes and analyzed by the PCAS. This system quantifies oncogenic activity in the majority of the oncogenic signaling pathways altered by the patients' mutations through a functional assay and does not rely on prior knowledge of the mutations. The system produces a quantitative output enabling grading the different mutants of the same patient, providing prioritization for better drug selection. In 3 tested genes, 16 different mutations were identified-4 in EGFR, 4 in PIK3CA and 8 in KRAS. Of these 10 were classified as known mutations for which functional annotation exists, and 6 were VUS. In addition to correctly annotating all known mutations, the PCAS further quantified oncogenic activity in all the VUS tested. Measuring the functional mechanism behind known mutations and VUS provides another layer of critical information to the physician. These results clearly demonstrate the value of a functional assay in accurately identifying the optimal course of treatment, particularly by its ability to add actionable information to VUS. The study produced a comprehensive delineation of the oncogenic activity of each patient's individual mutations demonstrating the ability of the PCAS to 1) accurately deliver comparable actionable information as found by NGS, 2) functionally characterize mutations annotated as VUS, and 3) monitor oncogenic activity of signaling pathways induced by different mutations and mutationcombinations enabling informed treatment decisions.
LB-B25
Consensus tissue-independent epithelial tumor subtypes and their differing responses to therapy. Anguraj Sadanandam. The Institute of Cancer Research, Sutton, United Kingdom.
Background: Epithelial cancers are highly heterogeneous, and each epithelial tumor is composed of a number of subtypes. It is becoming clear that the same dysregulated pathways are common to different tumors, regardless of their tissue of origin. Therefore, the goal of the current study was to identify intrinsic tissue-independent epithelial tumor subtypes by analyzing a large cohort of different epithelial tumors.
Methodology: Different gene expression profiles from various epithelial tumors (n=~5000) and cell lines (n=~200) from 12 different organs were merged using distance weight discrimination analysis, followed by consensus clustering using non-negative matrix factorization (NMF). The association of subtypes with response to various therapeutic compounds was identified using publicly available cell line drug response data.
Results: Three to seven consensus gene expression subtypes were identified and validated in the epithelial tumors and cell lines, irrespective of the tissue of origin. Certain epithelial subtypes were not present in melanoma or hematological cancers. The consensus subtypes had gene expression and biological profiles similar to normal epithelial and stem cells, and could be readily compared to the transcriptomic subtypes previously reported for individual epithelial tumor types. Moreover, specific gene signatures were identified that would be suitable as clinical assays in future applications of this classification system. There were significant differential responses between subtypes to different therapeutic compounds.
Conclusion: Several consensus transcriptomic subtypes were identified that are applicable to different organ-specific tumors. This study provides new avenues for precision therapy irrespective of the tissue of origin.
Late-Breaking Poster Session C The Jackson Laboratory, Bar Harbor, ME.
Humanized mice engrafted with tumors enable in vivo investigation of the interactions between the human immune system and human cancer. We have recently found that humanized NOD-scid IL2Rγnull (NSG) mice bearing patient-derived xenografts (PDX) allow efficacy studies of check-point inhibitors. Next generation NSG strains include triple transgenic NSG mice expressing human cytokines KITLG, CSF2, and IL-3 (NSG-SGM3). Here we provide a direct comparison of check-point inhibitors evaluation in NSG and NSG-SGM3 mice engrafted with CD34+ human hematopoietic progenitor cells (HPCs) from the same donor and implanted with PDX tumors. Corroborating earlier studies, reconstitution of human immune system in the blood was faster and more robust in NSG-SGM3 compared to NSG recipients throughout the course of the study (18 weeks). Human CD45+ cells reached 25% of total blood cells at week 4 in hu-NSG-SGM3 mice and at week 9 in hu-NSG mice. A majority of blood hCD45+ cells in hu-NSG-SGM3 at week 4 were CD33+ myeloid cells. Circulating hCD3+ T cells reached 10% at week 9 and included regulatory T cells (Tregs), consistent with earlier studies. Hu-NSG mice displayed comparable hCD3+ T cells in the blood only at 12-15 weeks and did not contain Tregs. PDX tumors were then engrafted into partially HLA-matched hu-NSG-SGM3 mice at 9 weeks post engraftment. Two PDX models previously shown to respond to anti-PD1 therapy in hu-NSG mice, BR1126 and LG1306, were used. Treatment with the anti-PD-1 receptor antibody pembrolizumab (Keytruda) significantly reduced tumor growth in both models. Thus, PDX-bearing hu-NSG-SGM3 mice might serve as a new and improved platform for preclinical immuno-oncology efficacy studies.
Late-Breaking Abstracts
Apoptosis, Necrosis, and Autophagy
LB-C02
A KRAS dependency microRNA signature reveals a p62/Sqstm1-centered autophagy network regulated by mir-124. ANITA K. MEHTA Background Non-small cell lung cancer (NSCLC) is derived from broncho-alveolar epithelial cells. NSCLCs frequently harbor mutations in the KRAS oncogene, yet only a subset of NSCLC cell lines depend on KRAS for sustained survival signaling. Cells that are more epithelial are highly KRAS dependent, whereas mesenchymal-like cells are KRAS independent for cell survival signaling. KRAS mutations are commonly associated with resistance to anti-cancer therapeutics. An important drug resistance mechanism is altered cellular plasticity, via a process known as epithelial-to-mesenchymal transition (EMT). Here, we aimed to identify and elucidate a KRAS dependent microRNA (miRNA) signaling network in epithelial cancer cells that modulates malignant growth and proliferation as well as cellular plasticity in NSCLC.
Methods Differential miRNA expression in 6 KRAS mutant NSCLC cell lines (3 KRAS independent versus 3 KRAS dependent) was determined using Taqman low-density qPCR arrays (TLDA). To explore the functional relevance of differentially regulated miRNAs, gain-of-function studies by reconstitution experiments were performed using miRNA mimics in a panel of six KRAS independent cell lines. The molecular targets of mir-124-2 were computationally identified by TargetScan or miRWalk and experimentally verified using 3'UTR luciferase-based assays. Functional rescue of cell viability defects was determined by forced expression of GFP-p62/Sqstm1 in KRAS independent lung cancer cell lines.
Results We identified a distinct differential miRNA expression profile in KRAS dependent versus KRAS independent NSCLC cells. This KRAS dependency miRNA signature included members of the mir-200 family, mir-34c and mir-205. Mir-200 and mir-205 reconstitution in KRAS independent cells modulated epithelial plasticity by down regulating Zeb1 protein expression and, thereby, increasing E-cadherin levels. Ectopic introduction of a subset of miRNAs in KRAS independent cells caused a consistent and pronounced loss of cell viability in all cell lines tested, including mir124, mir-625 and mir-518-3p. Ectopic expression of mir124 in KRAS independent cells caused cell viability defects by inducing apoptosis and autophagy. Using bioinformatics databases, we isolated p62/Sqstm1 and REL-A as key predicted targets of mir124-2. Mir-124-2 reconstitution in KRAS independent NSCLC cell lines caused decreased p62/Sqstm1 and REL-A protein expression levels. The effect of mir-124 on p62/Sqstm1 expression was verified using a p62-3'UTR-Luciferase construct. Overexpression of GFP-p62 in KRAS independent cells rescued the cell viability defects by mir124-2.
Conclusion MiR-124 expression is down regulated in KRAS independent NSCLC cells. Reintroduction of mir124-2 induces cell viability defects in part, by targeting p62/Sqstm1 and REL-A. We conclude that, mir-124 down regulates p62/Sqstm1 expression to activate autophagic flux. This leads to down regulation of the NFκB pathway and subsequent reduction in expression of pro-survival genes such as IL-6 and IL-1β. Taken together, mir124-2 acts as a tumor suppressor in KRAS mutant NSCLC cells and provides a mechanistic link between activation of autophagy and control of proinflammatory signaling in NSCLC cell survival. Overexpression of mir124-2 might be of potential therapeutic value for the treatment of KRAS mutant NSCLC.
LB-C03
Lovastatin induced anti-proliferation through multipathways in human intrahepatic cholangiocarcinoma. Yu-Chen Yang, Hung-Yun Lin. Taipei Medical University, Taipei City, Taiwan.
Human intrahepatic cholangiocarcinomas are one of the most difficult cancers to treat. Lovastatin, a 3-hydroxy-3-methylglutaryl-coenzyme-CoA (HMG-CoA) reductase inhibitor, exhibits anticancer properties. In this study, lovastatin inhibited cell proliferation, cell migration and cell adhesion. Results showed lovastatin inhibited the gene expressions of integrin β1 and integrin β3 but not integrin αv or integrin β5. Furthermore, gene expressions of transforming growth factor (TGF)-β1, cyclooxygenase (COX)-2 and intercellular adhesion molecule (ICAM)-1 were inhibited by lovastatin. Also, the cholesterol-depleting agent, methyl-betacyclodextrin (MβCD), reduced the expression of β3 integrin, but not that of the other genes in either cancer cell line. The lovastatin-induced inhibitory effects on expressions of TGFβ1, COX2, and ICAM-1 were positively controlled by the tumor suppressor, LKB1; however, the inhibition of integrin β3 by lovastatin was negatively affected by LKB1. The inhibitory effect of lovastatin on cell adhesion was associated with decreased expression of integrin β3 and the presentation of cell surface heterodimer integrin αvβ3. Furthermore, lovastatin strongly inhibited integrin αvβ3 downstream FAK activation, and the expression of β-catenin, vimentin, ZO-1, and β-actin. Therefore, in addition to the cholesterol-depleting effect, lovastatin modified the expressions of cell adhesion molecules leading to reduced tumor cell proliferation and migration. These advantageous effects of lovastatin may be mediated by blocking integrin β3 signaling suggesting a novel treatment option for cholangiocarcinomas.
Bioinformatics
LB-C04
Modeling the impact of somatic alterations across human cancers. Hatice U. Osmanbeyoglu, Christina Leslie. Memorial Sloan Kettering Cancer Center, New York, NY.
Large-scale cancer genomics projects like The Cancer Genome Atlas have generated a comprehensive catalog of somatic mutations and copy number aberrations across many tumor types, but the role of some frequently altered genes remains obscure. To better model the impact of these alterations, we developed a computational strategy for exploiting parallel phosphoproteomics and mRNA sequencing data for large tumor sets to link dysregulation of upstream signaling pathways with altered transcriptional response through the transcriptional circuitry. Our modeling allows us to interpret the impact of mutations and copy number events in terms of altered signaling and transcription factor (TF) activity. We used a novel machine learning strategy to train phosphoprotein-TF interaction models across 10 human cancers for which large reverse-phase protein array and RNA-seq data sets are available through TCGA. We then applied a novel algorithmic approach to extract networks of signaling proteins and TFs whose inferred activities are correlated across tumors and whose dysregulation is associated with specific somatically altered genes. Our analysis revealed both known and novel interactions of frequently altered genes with signaling pathways and transcriptional programs in a pan-cancer context. Moreover, our algorithmic approach provides a general strategy for modeling the impact of recurrent mutations and copy number alterations on signaling pathways and transcriptional programs through pan-cancer analysis. Background: The recent approval of several new targeted therapies for metastatic melanoma (including ipilimumab, an anti-CTLA-4 therapy) has introduced a new challenge for physicians to determine which drug(s) provide the most benefit to an individual patient. More effective strategies using blood or tissue biomarkers to identify patients who are responding (or not responding) to a particular therapy are needed.
Exosomes are abundantly released from tumors into biofluids such as plasma and carry nucleic acids and proteins from the cell of origin. This enables a non-invasive way to monitor a patient's tumor status in realtime. However, despite the many advantages of a liquid biopsy over traditional and invasive biopsy of primary tumors, there are challenges. Specifically, a biofluid-based cancer test for a tumor-specific exosome signature must be identified against a background of exosomes originating from non-malignant cells.
Here we set out to identify early changes in exosome mRNA that predict six month progression free survival (PFS) of metastatic melanoma patients treated with ipilimumab. To facilitate the identification of gene changes related to ipilimumab treatment, we examined exosome mRNA from patient plasma with and without exclusion of non-tumor exosomes. We predicted that depletion of normal reticulocyte exosomes using an anti-glycophorin A platform would enrich tumor-derived exosomes in plasma and reveal rapid exosome mRNA changes between baseline and week 2 or week 4 of treatment.
Methods: Plasma was obtained from 17 patients with metastatic melanoma before receiving ipilimumab (baseline) and longitudinally throughout treatment. Response to therapy was determined by RECIST. Patients who achieved at least six months PFS from start of ipilimumab (n=7) were compared to patients with progressed disease (PD) on ipilimumab (n=10).
Matched patient plasma samples at baseline and week 2 or week 4 were analyzed. The plasma exosome mRNA signature using the glycophorin A exclusion method was compared with total plasma exosome mRNA from the same patient samples. Analysis of exosomal mRNA utilized the OpenArray® Human Inflammation Panel. Fold change in gene expression between baseline and week 2 or 4 was calculated.
Results: Targeting glycophorin A to remove normal reticulocyte exosomes from plasma enriched the RNA profile compared to total exosome profiling. Of the 587 genes examined, the exclusion platform revealed 28 genes that were significantly increased between baseline and 2-4 weeks in the majority of patients who went on to achieve 6 month PFS, and decreased in patients with PD. This signature included immune-related genes such as CCR5, INFAR1, LTB, MALT1 and TNFSF8. In contrast, the exosome mRNA signature without the exclusion platform revealed only four genes that changed between baseline and week 2 or 4: A2M, CD163, TLR1 and TNFSF10.
Conclusions: We have developed a platform to exclude normal exosomes from plasma which increases the power to discriminate early exosome mRNA changes associated with improved progression free survival in metastatic melanoma patients in response to ipilimumab. Future work will focus on refining and validating the mRNA signature.
LB-C06
Early prognostic significance of circulating laminin γ2-chain fragment in non-small-cell lung cancer. Yu Teng, Li Ma, Xiaoting Zhao, Lina Zhang, Meng Gu, Yue Wang, Wentao Yue. Beijing TB and thoracic tumor research institution, Beijing, China.
Background: Laminin γ2-chain (Ln-γ2), a distinctive subunit of heterotrimeric laminin-332, is frequently upregulated in various types of carcinomas, and is of great importance in the biological processes including cell migration and tumor invasion. Despite of this, the status of circulating Ln-γ2 fragment in lung cancer patients is still uncertain.
Methods: In this study, serum samples from 538 all-stage (stage I-IV) patients of non-small-cell lung cancer (NSCLC) and 94 age-matched normal volunteers were determined by enzyme-linked immunosorbent assay. Data were statistically analyzed in combination with clinicopathological information.
Results: Compared to the normal controls, serum Ln-γ2 concentration is drastically increased in NSCLC patients (P < 0.001), even in early cases of stage I patients (P < 0.001). Furthermore, our data suggested that serum Ln-γ2 level was in close correlation to male gender (P < 0.001) and smoking status (P < 0.001) with a higher positive rate relative to each counterpart, but was not significant between adenocarcinoma and squamous cell carcinoma histologies (P = 0.879). We also found that circulating Ln-γ2 could reflect the progression of lung cancer with higher serum levels or positive rates in higher tumor-node-metastasis (TNM) stages. Survival analysis on 370 eligible patients who underwent a follow-up examination up to 4 years indicated that patients of serum Ln-γ2 positive group survived markedly shorter compared with those in the negative group (P = 0.028), and it was especially the case for clinical stage I (N = 72, P < 0.001) and stage T1 (N = 67, P = 0.001), even for stage N0 patients (N = 148, P = 0.038), which all represent groups of early cases. As for the patients of advanced stages, however, it was not the case that the overall survival rates between Ln-γ2 positive and negative patients were not significantly different among clinical stages II-IV (P = 0.830), stages T2-4 (P = 0.575), stages N1-3 (P = 0.669), and stage M1 (P = 0.849) groups, respectively. Subsequently, Cox regression analysis was performed to define serum Ln-γ2 as an independent prognostic indicator in the all-stage NSCLC cases (N = 370, univariate, P = 0.035; multivariate, P = 0.007). Worthy of note, however, in the multivariate analysis on those more advanced cases (stage II-IV), no statistical significance was observed on the serum levels of Ln-γ2 (N = 298, P = 0.234).
Conclusion: In summary, our study suggests circulating Ln-γ2 to be a promising diagnostic biomarker for early-stage NSCLC and an effective indicator of tumor progression. It is proposed that circulating Ln-γ2 might be important and applicable for the prognosis of early-stage NSCLC patients, rather than that of advanced cases.
LB-C07
Predictive biomarkers for detection and therapeutic response in genitourinary cancers using enumeration of circulating tumor cells. Robert J. Amato Introduction: Genitourinary (GU) cancers are common tumor types that have multiple therapeutic options, but the cure rate is low, and adaptation or acquired resistance to treatment are common. Biomarkers are lacking in these cancer types; thus, it is essential to develop a reliable, reproducible biomarker of detection, treatment guidance, and prognosis, such as enumeration of circulating tumor cells (CTCs). The challenge of CTCs has been the ability to capture mixed cell populations. We describe the results of a concept study using the Axon nCYTE Dx TM System to enumerate EpCAM-positive and -negative CTCs from patients with prostate, bladder, and renal cell cancer at various stages of disease.
Methods: One-time clinical blood samples (10 mL) were obtained from 50 patients with GU cancers; 6 mL (3 mL/slide) were used to enumerate CTCs (4 mL were stored for future study). Nucleated cells were fixed, permeabilized, and pelleted. Cell pellets were then rinsed and incubated in a proprietary cancer detection cocktail and run through the Axon nCYTE Dx TM detection/enumeration instrument to detect and count CTCs (nucleus+/cytokeratin; non-specific binding-). All data was analyzed in a blinded manner.
Results: The Axon nCYTE Dx TM System was able to isolate CTCs from all patient samples analyzed to date. CTC (>4 µm) purity after the first enrichment step was in 100% (median, 2.1/mL; mean, 2.2/mL) of prostate samples, 100% (median, 2.1/mL; mean 2.1/mL) of bladder samples, and 100% (median, 1.6/mL; mean, 9.1/mL) of renal cell samples. We present data on the first 10 patient samples (table 1); another 18 are being analyzed and 22 being accrued.
Conclusions: The Axon nCYTE Dx™ System consistently detected CTCs among various subsets of patients with GU cancers. We are in the process of completing accrual and analysis of remaining patient samples. A complete data set will be presented at the meeting. Our initial proof of principle will be prospectively validated longitudinally as a complement to our clinical research program in GU cancers to establish CTCs as a biomarker of detection, treatment response, and prognosis.
LB-C08
Exploring glycan markers for immunotyping and precision-targeting of breast circulating tumor cells (CTCs). Lidia C. Sambucetti Recognition of abnormal glycosylation in virtually every cancer type has raised great interest in exploration of the tumor glycome for biomarker discovery. Identifying glycan markers of circulating tumor cells (CTCs) represents a new development in tumor biomarker discovery. The aim of this study was to establish an experimental approach to enable rapid screening of CTCs for glycan marker identification and characterization. We applied carbohydrate microarrays and a high-speed fiber-optic array scanning technology (FASTcell) to explore potential glycan markers of breast CTCs (bCTCs) and targeting antibodies. An anti-tumor monoclonal antibody, HAE3-C1 (C1), was identified as a key immunological probe in this study. In our carbohydrate microarray analysis, C1 was found to be highly specific for an O-glycan cryptic epitope, gpC1. Using FASTcell technology, we established a procedure to quantify expression levels of gpC1 in tumor cells. In blood samples from five Stage IV metastatic breast cancer patients, the gpC1 positive CTCs were detected in all subjects; approximately 40% of bCTCs were strongly gpC1 positive. Interestingly, the CTCs from a triple-negative breast cancer patient with multiple sites of metastasis were predominantly gpC1 positive (92.5%, 37/40 CTCs). Taken together, we present here a practical approach to examine rare cell expression of glycan markers. Using this approach, we identified an O-core glyco-determinant gpC1 as a potential immunological target of bCTCs. Given its bCTC-expression profile, this target warrants an extended investigation in a larger cohort of breast cancer patients.
Cancer Stem Cells
LB-C09
Hematological and neurological expressed 1-like (HN1L) is a novel therapeutic target for triple-negative breast cancer. Dong Soon Choi Background and Objective: Triple negative breast cancer (TNBC: ER-,PR-,Her2-), is characterized by its aggressive clinical behavior with high incidence of visceral metastasis to the lungs and brain. These patients do not respond to hormonal therapy and show intrinsic resistance to conventional chemotherapy. Robust evidence indicates that treatment-resistance and metastases may arise from a subpopulation of cells with tumor-initiating capacity called breast cancer stem cells (BCSC). We are one of the first groups to demonstrate that residual tumors after exposure to chemotherapy are enriched for BCSC (Li et. al, J Natl Cancer Inst 100:672-9, 2008 ). We have previously described a tumorigenic treatment-resistant gene signature of 493 genes derived from patient biopsies (Creighton et. al, Proc Natl Acad Sci USA 106:13820-5, 2009 ).This finding narrowed down the possible cancer stem cell growth related genes from genome wide to only 493 genes and provided candidate genes for screening potential targets that affect BCSC self-renewal. Further screening and re-evaluation of the candidate genes determined a previously unidentified cancer gene, Hematological and Neurological Expressed 1-Like (HN1L) as the target of cancer stem cell self-renewal. HN1L is known to be involved in embryo development, but has been remained as an orphan gene. Thus, the objective of this study was to investigate the role of HN1L in in TNBC and to validate HN1L as a novel therapeutic target.
Results: We found from the TCGA database that the expression of HN1L is up-regulated in more than 20% breast cancer and is negatively correlated with relapse-free survival in TNBC patients. Silencing of HN1L considerably suppressed BCSC population in vitro and in vivo, sensitized tumors to chemotherapy in vivo, and substantially reduced lung metastasis. Mechanistically, our study identified HN1L as an novel and putative transcription factor regulating expression of STAT3 and the related regulatory genes including Leptin-receptor (Lepr) and miR-150. These upstream pathways converge to result in a persistent activation of a STAT3-regulated gene network promoting downstream BCSC self-renewal pathways. Correlatively, the TNBC patients exhibiting gene signature from HN1L knockdown tend to survive longer.
Conclusion: we described here for the first time that HN1L is a novel therapeutic target for triple negative breast cancer. This study highlights the importance of targeting HN1L that deactivates STAT3 and abrogates its function in BCSC self-renewal. Further investigation of HN1L in TNBC-targeted therapies will offer new strategies to treat this aggressive disease.
LB-C10
Identification of therapeutic targets for chemotherapy-resistant colon cancer stem cells. Maria Giovanna Francipane Current first-line chemotherapy generally consists of cytotoxic agents. While these agents may initially control disease by effectively debulking tumors, the tumors invariably recur due to the ability of cancer stem cells (CSCs) to survive and repopulate the tumor mass.
To identify potential molecular targets in 5-fluorouracil (5-FU) refractory CSCs, we developed 5-FU resistant cell lines over a period of a year.
Here we show that 5-FU maintains colon CSCs in an undifferentiated state in vitro. While untreated control cells passaged in parallel progressively acquired a differentiated morphology comprising crypt-villus structures, cells treated with an IC50 dose or escalating doses of 5-FU organized in round colonies with defined edges. Cells from these chemoresistant colonies exhibited a high nucleus-to-cytoplasm ratio and prominent nucleoli, features of pluripotent stem cells. Chemoresistant cells showed a reduced proliferation rate with respect to their counterparts. While immunofluorescent analysis revealed chemoresistant cells expressed a panel of pluripotency markers, flow cytometric analysis indicated a change in CD antigens associated with tumorigenicity and pluripotency in chemoresistant cells as compared to untreated cells. These results suggest colon CSCs, while under the selective pressure of chemotherapy in vitro, are likely to display an adaptive plasticity resembling fate reprogramming.
Three-dimensional growth in Matrigel revealed untreated cells were able to arrange themselves in a ring around a well-defined central lumen. Conversely, chemoresistant cell-derived organoids had poorly defined or no central lumens. While untreated cells generated fast-growing, well-differentiated tumors, resistant cells generated slow-growing, moderately differentiated tumors in vivo.
Late-Breaking Abstracts
Finally, a large number of genes were screened in cell/tissue from both groups using Real-Time PCR arrays. Through this analysis, we identified molecular targets that might assist in the development of therapeutic strategies which will counteract the mechanisms of chemoresistance.
Cell Cycle Regulators
LB-C11
HTLV-1 Tax-induced apoptosis to counteract tumor drug resistance. Vanessa C. Ducas, Gary M. Kupfer. Yale University School of Medicine, New Haven, CT. p53 mutations have been identified in over 50% of human cancers. As p53-mutant tumor cells have an inherent resistance to therapy-induced apoptosis, such a mechanism of resistance is an important problem in cancer therapy. Interestingly, Tax, a protein expressed by the human T-cell lymphotropic virus type 1 (HTLV-1), increases the sensitivity of p53-mutant and p53-null cells to DNA-damaging drugs. Tax-induced chemosensitivity presents therefore a novel strategy that can be exploited to counteract p53-mutant tumor resistance. The objective of this work is to harness the chemosensitizing property of Tax and use it to develop a chemotherapeutic approach that can overcome the drug resistance observed in p53-mutant/p53-null cancers. We hypothesize that Tax initiates a proapoptotic response in cancer cells by modulating cyclindependent kinase 4 (CDK4) activity. We use a combination of in vitro and in silico analyses to determine the mechanism of Tax-induced chemosensitivity and to identify small molecules that can phenocopy the CDK4-activating and the proapoptotic effects of Tax. Immunoblot analyses and in vitro kinase assays reveal that Tax alters CDK4 expression and activity. In addition, flow cytometry and gene expression studies respectively indicate that Tax expression promotes G1-to-S phase transition and leads to increased expression of the TP73 gene, a known homolog of TP53. Moreover, our in silico analyses, using an N-terminal construct of Tax and a published structure of CDK4 (PDB 3G33), reveal that CDK4 interacts with the Tax construct via a C-terminal domain that is distinct from its nucleotide-binding and D-type cyclin-binding sites. Further analyses identify ten small molecule mimics of Tax and putative CDK4 activators, which we show have a proliferative effect on treated cells. Although the focus of ongoing studies in the field has been the development of kinase inhibitors, several tumors develop strategies allowing them to override the effect of those inhibitors. Our work adopts a different strategy that will maximize the cytotoxic effect of anticancer drugs to overcome acquired drug resistance.
Cellular Responses to Therapy
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Functional proteomics elucidates signaling adaptation driven by combination therapy in BRAF mutant melanoma cell line models. Ritin Sharma Targeted kinase inhibition is a promising treatment modality for melanoma, which has significantly increased available clinical strategies and improved survival outcomes for patients, whose tumors harbor the BRAF V600E mutation. However, responses are transient and multiple mechanisms for drug resistance can contribute to therapeutic escape. Therefore, a novel multiplexed proteomics approach provides an optimal choice for comprehensively dissecting multiple mechanisms of resistance to BRAFi and combination therapy within one experiment.
A large-scale quantitative expression proteomics and phosphoproteomics analysis (SysQuant) was carried out on BRAF V600E mutant melanoma cell lines treated with two different clinically relevant kinase inhibitor combinations: 1) BRAFi/MEKi and 2) BRAFi/PI3Ki. Changes in protein expression and phosphorylation in response to each treatment are determined by comparison to vehicle controls. Cell line models all harbor BRAF V600E mutations, but differ in PTEN status (A375 is WT, while WM793 is PTEN null). Briefly, cells were treated with either drug combination (as above) and harvested at 1hr, 6hrs, 24hrs and 48hrs posttreatment. Control cells were treated with DMSO. Samples were lysed, reduced, alkylated and digested with trypsin. Tryptic peptides from each sample were chemically labeled or "barcoded" with TMT-10plex reagents (4 BRAFi/MEKi time points, 4 BRAFi/PI3Ki time points, 1 DMSO control and a pooled reference sample) and combined for LC-MS/MS. After peptide fractionation with strong cation exchange chromatography and phosphopeptide enrichment, LC-MS/MS peptide sequencing and relative quantification was performed using an Orbitrap Fusion mass spectrometer (Thermo). Raw MS data was searched by Proteome Discoverer and analyzed by in-house R-scripts and Perseus statistical software package. Pathway analysis was done in GeneGO (Metacore).
The SysQuant workflow identified >9,000 protein groups and >17,000 unique phosphosites per cell line across different treatments. Principal component analysis of the phosphoproteomics data revealed signaling differences across different treatment conditions and drug combinations are mainly driven by BRAFi and the time post-treatment. K-means clustering was also used to examine trends in the data; as an example, this technique could be used to track signaling changes that correlate with reduction and recovery in ERK signaling. The SysQuant approach provides a systems view of global signaling changes occurring in response to drug treatment. The ability to multiplex samples with TMT allows quantitative deduction of protein expression and phosphorylation patterns that are common or unique in different cell lines, time post-treatment and the effect of combination treatments.
This proteomics approach ties protein expression and phosphorylation status in response to combination therapy and generates several hypotheses for further testing with the goal of developing novel combination therapy strategies.
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Selective GPR55 antagonism attenuates EGFR-PKM2-β-catenin signaling and reduces chemoresistance in PANC-1 pancreatic cancer cells. Nagendra Singh G protein-coupled receptor GPR55 possesses pro-oncogenic activity, but the nature of GPR55 signaling pathways in mammalian tumor cells remain unclear. The effect of (R,R')-4'-methoxy-1-naphthylfenoterol (MNF), a potent GPR55 competitive inhibitor, on the expression of cancer biomarkers, such as EGFR, PKM2, Β-catenin and HIF-1Α, was investigated in human pancreatic cancer cell line, PANC-1. We also examined the modulation in expression of P-glycoprotein (Pgp) and other multidrug resistance drug exporters (MDR) in response to MNF. Incubation of PANC1 cells with MNF (1 μM) for 24h significantly decreased EGFR (~2-fold), PKM2 (~2.5-fold) and Β-catenin (~2-fold) protein levels and was accompanied by significant reduction in nuclear accumulation of HIF-1A(~1.5-fold) and phospho-active forms of PKM2 (~3-fold) and B-catenin (~2-fold). MNF and the GPR55 antagonist CID16020046 consistently reduced the expression of Pgp (~2-fold), BCRP (~2-fold), MRP1 (~1.5-fold) and MRP5 (~1.5-fold) in total cellular extracts while diminishing the nuclear expression of Pgp (~2.5-fold) and BCRP (~4.5-fold). Further, a significant increase in the nuclear accumulation of doxorubicin was observed in MNF-treated PANC-1 cells using laser scanning confocal microscopy. Importantly, a 24-h preincubation with MNF increased the cytotoxicity of doxorubicin (IC50 reduced from 170nM to 24nM) and gemcitabine (IC50 reduced from 486nM to 157nM) in PANC-1 cells. In the mouse xenograft model, daily MNF treatment (10mg.kg-1, i.p.) for 21 days led to a ~2-fold reduction in the expression of EGFR, PKM2, β-catenin and Pgp in PANC-1 tumor tissue relative to vehicle-treated controls (P < 0.001). These data suggest that MNF exerts its antitumor effects by inhibiting GPR55-mediated activation of select cancer biomarkers, and suppressing multidrug resistance to chemotherapeutic agents in pancreatic cancer cells. Objective: The objective of this retrospective analysis was to evaluate the correlation between preclinical and clinical markers of efficacy, using available monotherapy data for AstraZeneca targeted oncology drugs.
Methods: For each drug, preclinical/clinical parameters were identified, including; dose/dosing schedule, tumor model, pharmacokinetic parameters (AUC, t 1/2 ), clinically relevant dose (CRD), tumor growth inhibition (TGI), objective response rate (ORR), disease control rate (DCR), mean tumor shrinkage (MTS), and protein binding. Drugs were first examined to compare the concentrations (C av ) seen at CRDs to preclinical thresholds defined by the concentration required for 50% target inhibition (IC 50 ). Each drug had a number of associated IC 50 values, and in vivo values were preferentially used as the concentration target when available. Free C av values were calculated from AUCs, and a ratio of C av /IC 50 > 1 was used to determine whether the clinical drug exposure exceeded the preclinical efficacy target concentration.
The second objective was to determine the correlation between preclinical and clinical efficacy. This was accomplished by estimating murine TGI for each drug at either the allometrically-scaled, mouse-equivalent CRD or at the free exposure (CRE) seen in humans using a variety of dose-response models. Linear regression, weighted by the number of patients from whom clinical data was available, was performed on each comparison, and ANOVA was used to test the significance of each relationship using R v.3.2.2.
Results: Seventeen targeted drugs with clinical efficacy data were identified. A total of 9/15 (60%) drugs with available data exceeded a free C av /IC 50 ratio of 1 (ratio range of target attaining drugs: 3.6-63.3), indicating that target concentration had been achieved in those drugs.
Tumor growth inhibition predicted by the mouse-equivalent CRD ranged from 0.5-155.7% across 13 drugs, while it ranged from 53.4-179.9% across 9 drugs for which TGI could be predicted from the CRE. The weighted correlation between CRD-TGI and clinical ORR was significant (r = 0.71, p < 0.01), while the correlation between CRE-derived TGI and ORR was not (r = 0.46, p = 0.12). While MTS data was only available for the late-stage and approved drugs (6/17 drugs), the linear relationship between CRD-TGI and clinical MTS was significant as well (r = 0.90, p < 0.01). Based on the CRD-TGI regressions, a TGI of 46% translated into a ORR of 10%. Similarly, a TGI of 63% resulted in a clinical MTS of 10%.
Conclusions: Comparison of preclinical concentration targets and clinical exposures suggests that the CRD is only achieving the preclinical target in just over half of the drugs, highlighting the importance of choosing a relevant in vivo preclinical concentration to target clinically.
Conversely, a high correlation between CRD-based TGI and clinical ORR was observed suggesting that this marker may be more appropriate for prediction of clinical efficacy from preclinical data.
Overall, this study demonstrated a correlation between dose-predicted TGI and clinical efficacy. Although this is a small data set, this study confirmed the importance of setting an efficacy threshold preclinically before moving into the clinic with oncology targeted drugs.
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Safety and tumor responses of the anti-Trop-2 antibody drug conjugate, sacituzumab govitecan (IMMU-132), in refractory, metastatic, triple-negative breast cancer ( 1 models. Using in vitro proliferation assays and immunoblot analysis, we determine that savolitinib rapidly inhibits cMET auto-phosphorylation/activation and reduces the viability of NSCLC cell lines NCI-H1993 and EBC-1 with a GI 50 of 4.20 nM and 2.14 nM, respectively. In vivo, once daily treatment of NCI-H1993 xenografts with 3.0 mg/kg savolitinib significantly slows tumor growth, whereas treatment of EBC-1 xenografts with 30.0 mg/kg results in tumor stasis. Importantly, we observe tumor regressions in a patient-derived xenograft model of a NSCLC lymph node metastasis, HLXF-036LN, dosed with savolitinib 50.0 mg/kg once daily. Pharmacodynamic analysis of in vitro and in vivo models shows that savolitinib sensitivity correlates with blockade of PI3K/AKT and MAPK signaling, and interestingly, with cMYC (MYC) protein down-regulation. To elucidate mechanisms of acquired resistance in NSCLC, we generated savolitinib resistance in vitro using the NCI-H1993 and EBC-1 cell lines and further sub-cloned resistant NCI-H1993 cells to study the heterogeneity of resistance mechanisms. Using small-molecule screening, phospho-protein arrays and interrogation of signaling pathway activity by immunoblot, we identify 1) deregulated mTORC1/2 signaling and 2) the uncoupling of MYC expression from cMET activation as commonly contributing to resistance in all clones tested. RNA interference (siRNA) and MYC over-expression experiments confirm the novel finding that sustained MYC expression can partially drive resistance to a tyrosine kinase inhibitor such as savolitinib. Additionally, we identify clone-specific resistance mechanisms arising via a previously-described switch to EGFR dependence or by our novel finding of a de novo requirement for PIM signaling. Taken together, this work demonstrates the preclinical efficacy of savolitinib in NSCLC and provides an initial characterization of potential resistance mechanisms, identifying core resistance targets and clone-specific vulnerabilities that could be exploited to counter acquired savolitinib resistance that may emerge in the clinic.
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A haploid genetic screen identifies the G1/S regulatory machinery as a determinant of Wee1 inhibitor sensitivity. Anne Margriet Heijink The Wee1 cell cycle checkpoint kinase prevents premature mitotic entry by inhibiting cyclin-dependent kinases. Chemical inhibitors of Wee1 are currently being tested clinically as targeted anti-cancer drugs. Wee1 inhibition is thought to be preferentially cytotoxic in p53-defective cancer cells. However, TP53 mutant cancers do not respond consistently to Wee1 inhibitor treatment, indicating the existence of genetic determinants of Wee1 inhibitor sensitivity other than TP53 status. To optimally facilitate patient selection for Wee1 inhibitor treatment and undercover potential resistance mechanisms, identification of these currently unknown genes and underappreciated functions of Wee1 is necessary. The aim of this study was to identify gene mutations that determine Wee1 inhibitor sensitivity.
We performed a genome-wide unbiased functional genetic screen in TP53 mutant near-haploid KBM-7 cells using gene-trap insertional mutagenesis. Insertion site mapping of cells that survived long-term Wee1 inhibition revealed enrichment of G1/S regulatory genes, including SKP2, CUL1 and CDK2. Stable depletion of SKP2, CUL1 and CDK2 or chemical Cdk2 inhibition rescued the γ-H2AX induction and abrogation of G2 phase as induced by Wee1 inhibition in breast and ovarian cancer cell lines. Remarkably, live cell imaging showed that depletion of SKP2, CUL1 and CDK2 did not rescue the Wee1 inhibition-induced karyokinesis and cytokinesis defects. These data indicate that the activity of the DNA replication machinery, beyond TP53 mutation status, determines Wee1 inhibitor sensitivity, and could serve as a selection criterion for Wee1-inhibitor eligible patient. Conversely, loss of the identified S-phase genes could serve as a resistance mechanism and coincides with development of severe genomic instability.
LB-C24
Resistance to ALK inhibition is associated with enhanced BRD4 dependence in ALKmutated MYCN-amplified neuroblastoma. David Debruyne, Bandana Sharma, Nathanael Gray, Rani George. Dana-Farber Cancer Institute, Boston, MA.
Despite substantial therapeutic advances, the long-term survival rate of patients with high-risk neuroblastoma (NB), a tumor of the peripheral sympathetic nervous system is still dismal. Activating mutations in the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase represent promising therapeutic targets in this disease and have prompted clinical trials of ALK inhibitors. But as with all molecularly targeted therapies, resistance is inevitable and will limit the ultimate utility of this therapeutic strategy. To elucidate the mechanisms of resistance to ALK inhibitors, we have generated isogenic NB cells, expressing the tumorigenic ALKF1174L mutation and amplified MYCN, with acquired resistance to the ALK inhibitor TAE684, through continuous exposure of increasing concentrations of the compound over time. We found that resistance was associated with downregulation of ALK activity, thus ruling out secondary mutations as a mechanism of resistance, and interestingly the other major oncogenic driver in neuroblastoma, MYCN, was downregulated as well. A comparative genome-wide expression analysis revealed global transcriptional downregulation in the resistant cells, as compared with their parental sensitive counterparts, in accordance with the aforementioned MYCN downregulation, as MYCN is known to act as a transcriptional amplifier in MYCN-amplified NB cells. Additionally, these resistant cells exhibited a 10-fold increased sensitivity to the BRD4 inhibitor JQ1, compared to sensitive cells, and MYCN as well as global gene expression were rescued after treatment. These results strongly suggest that resistance to ALK inhibition in ALKF1174L MYCN-amplified NB cells leads to a MYCN-independent enhanced BRD4 dependence, therefore providing a rationale for the use of BET inhibitors to overcome such resistance. Studies are currently underway to characterize the unique epigenetic landscape driving the resistant cells' survival and therefore identify novel targets that could be taken advantage of in future therapeutic strategies.
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Inhibition of ERBB3 with MM-121, IGF1-R with MM-141 or Met with MM-131 increases the activity of EGFR inhibitor MM-151 in colorectal cancer models expressing multiple resistance ligands. Marisa J. Wainszelbaum, Jessica Fessler, Johanna Lahdenranta, Olga Burenkova, Nat GeramiMoayed, Yasmin Hashambhoy-Ramsay, Victoria Rimkunas, Gavin MacBeath. Merrimack Pharmaceuticals, Cambridge, MA.
Introduction: The Epidermal Growth Factor Receptor (EGFR) pathway is a key driver of late-stage colorectal cancer (CRC) and EGFR inhibitors, such as cetuximab and panitumumab, prolong survival in a large subset of patients. Not all patients respond to EGFR inhibitor therapy, however, and resistance develops in those who respond. Accumulating evidence suggests that alternative signaling pathways circumvent EGFR blockade. Several studies have shown that tumors with high heregulin, IGF-1 or HGF respond poorly to EGFR-targeted therapies. Further, Phase 2 studies suggest that combined inhibition of EGFR and HGF with panitumumab and rilotumumab significantly improves response rates compared to panitumumab alone. These data support the notion that more than one pathway may be simultaneously active in late-stage CRC and that EGFR-directed therapy may be improved through combination strategies.
Merrimack has built a portfolio of biologic agents targeting key oncogenic receptors that block ligand binding and pathway activation, providing a unique opportunity to develop combination therapies in a biomarker-driven fashion. MM-151 targets EGFR; MM-121 (seribantumab) targets ERBB3; MM-141 (istiratumab) targets both IGF-1R and ERBB3; and MM-131 targets Met and EpCAM. Here we investigate responsiveness to different resistance ligands and the ability of drug combinations to block ligand-mediated cell growth more effectively than monotherapy.
Experimental procedures: We evaluated the prevalence of resistance ligands in colorectal adenocarcinoma patient samples by RNA in situ hybridization. To assess the effect of ligands and drugs on cell growth we
